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ABSTRACT 
 
 PANcreatic-DERived Factor (PANDER), or FAM3B, is a 235-amino acid protein strongly 
expressed within and secreted from the endocrine pancreas. Research surrounding PANDER has 
revealed a large role for the protein in maintaining glucose homeostasis, as evidenced by 
several Ad-PANDER overexpressing murine models, our lab’s pancreas-specific PANDER 
transgenic overexpressor, and most recently our mixed genetic C57/129J PANDER knockout 
(PANKO) mouse. However, PANDER’s overall role in glycemic regulation and glucose 
homeostasis has yet to be studied in a purebred C57BL/6J PANDER knockout model. Here we 
present the first phenotypic characterization of our global PANDER knockout mouse on a 
C57BL/6J background (PANKO-C57) where we examined metabolics through glucose/insulin 
tolerance testing, fasting glycemia, and body weights, the concentrations of hormonal analytes 
along with lipids and corticosterones, and full elucidation of hepatic insulin signaling through the 
insulin signaling cascade. Overall, the PANKO-C57 mice exhibited increased body weights with 
enhanced glucose tolerance and lower fasting glycemia, similar peripheral insulin sensitivities, 
increased hepatic lipidemia, and enhanced hepatic insulin signaling at critical insulin signaling 
molecules. Taken together, the PANKO-C57 demonstrates that the disruption of PANDER results 
in selectively enhanced hepatic insulin signaling yet with increased lipidemia and overall body 
weight. These findings reveal a novel role for PANDER in differentially controlling lipogenesis 
and hepatic glucose production that may selectively impact overall glycemic control and 
potentially facilitate the onset and/or progression of type 2 diabetes. 
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CHAPTER ONE: INTRODUCTION 
 
Typical Glycemic Regulation 
 Glycemic regulation, or the maintenance of glucose homeostasis within the body, is a 
process that is tightly regulated by not only numerous hormones but also by many organs 
including the brain, liver, pancreas, skeletal muscle, and even the intestines [1-4]. The brain, in 
particular, relies on glucose as its main source of energy and oxidation to function and conduct 
processes through all neuronal tissue. In conditions where glucose in the blood is low, or 
hypoglycemia, the brain’s functions become abnormal and can ultimately lead to death [2]. 
However, by working cooperatively with the liver, pancreas, and skeletal muscle, the brain is 
allowed to operate properly while still allowing for optimal glucose homeostasis through glucose 
production and subsequent utilization [1-4]. It is most important that the maintenance of 
glycemia is tightly regulated especially in times of fasting and fed when blood sugar 
concentrations fluctuate so greatly. The balance of various hormones from the brain, gut, and 
pancreas secreted at optimal times in response to fluctuating blood glucose allow for maximal 
functioning of glycemic regulation and glucose homeostasis. 
 Fed State Glycemic Regulation 
 The balance between glucose entrance into and departure from the bloodstream is at 
the forefront of importance in maintaining proper glucose homeostasis. The primary source of 
circulating glucose is through ingestion of a meal (fed state/postprandial) and subsequent 
gastric emptying by digestive enzymes [1, 4, 5]. The regulation of postprandial circulating 
glucose appearance is due, in large part, to the action of 2 hormones referred to as incretins- 
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GIP (Glucose-dependent Insulinotropic Polypeptide, formerly Gastric Inhibitory Polypeptide) and 
GLP-1 (Glucagon-Like Peptide 1). GIP and GLP-1 are secreted from intestinal K-cells and L-cells, 
respectively, in response to oral ingestion of a meal that is rich in carbohydrates and/or fats [1, 
4, 5]. Their mechanisms of action differ, however, in that although they both stimulate the 
biosynthesis and release of insulin from pancreatic β-cells, GLP-1 slows gastric emptying to 
properly correlate glucose appearance with timely release of insulin and prevents glucagon 
secretion whereas GIP works primarily in adipose tissue for fat metabolism [4, 5, 25]. Their 
levels under normal glycemic conditions differ, too, in that because GLP-1 is more 
physiologically relevant to humans, it fluctuates from levels being high postprandially and much 
lower when fasting [1]. Taken together, GIP and GLP-1 work cooperatively with insulin and 
glucagon to speed glucose disappearance to surrounding tissues and organs after oral nutrient 
uptake. Additionally, amylin, a neuroendocrine hormone secreted by pancreatic β-cells with 
insulin, works in concert with insulin to increase glucose disappearance and slow gastric 
emptying to prevent spikes in blood glucose [8]. Perhaps more importantly, amylin suppresses 
glucagon, a hormone secreted by pancreatic α-cells (and inhibited by insulin) in times of fasting 
when plasma glucose levels are low to enhance hepatic glucose production (HGP) [1, 8, 9]. By 
suppressing the action of glucagon postprandially, amylin chiefly regulates the appearance of 
endogenous glucose from the liver in addition to exogenous glucose from meal intake [1] 
(Summarized in Figure 1). Insulin, a potent anabolic hormone, also allows for glucose utilization 
through the process of glycolysis [2, 6]. When insulin is released from pancreatic β-cells 
through GLP-1 and GIP stimulation, there is a consequential rise in plasma insulin levels, 
triggering the uptake of glucose into cells for oxidation.  When glucose is transported into 
muscle, liver, and fat cells through glucose transporters, it is shuttled through the oxidative 
process of glycolysis and The Citric Acid (TCA) Cycle to yield ATP for cellular energy [1, 4, 5, 8]. 
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Figure 1: Fed State Network of Interactions in Normal Glycemic Regulation. Illustration 
representing the normal regulation of glycemia in the fed state, beginning with nutrient stimulation from 
the brain, stimulating the simultaneous release of amylin with insulin stimulated by GLP-1 and GIP. 
Amylin and GLP-1 slow gastric emptying and GLP-1 works with insulin to inhibit glucagon secretion in 
turn decreasing glucose output while plasma glucose and consequent glucose disappearance increases 
(adapted from Aronoff et al., 2004 [1]) 
  
 Fasting State Glycemic Regulation 
 On the other hand, under fasting conditions when circulating glucose is scarce, the liver 
is utilized to upregulate glucose output into circulation through two discrete mechanisms. HGP 
is accomplished in the liver by breaking down glycogen through glycogenolysis and also via de-
novo synthesis from amino acids and other carbon derivatives through gluconeogenesis [1, 2, 
6]. First, glucose is stored within the liver (and muscle) as glycogen, a highly branched 
polymerized molecule with an α-(1, 6) linkage every 10 glucose residues that carries an average 
of 4 kcal of energy per gram of tissue [1, 2]. Under the control of the hormone glucagon (when 
plasma insulin levels are low) and in fasting conditions up to 8-12 hours, glycogenolysis is the 
primary source of glucose output from the liver [1, 9]. The hydrolysis of glycogen is initiated 
with the cleavage of a single glucose-1-phosphate molecule off of the branched polymer by 
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glycogen phosphorylase, activated by the binding of glucagon to its putative receptor on the 
plasma membrane. Then, the glucose-1-phosphate molecule is converted to glucose-6-
phosphate, a gluconeogenic intermediate, to be acted on by glucose-6-phosphatase (G6Pase), 
where it is then converted to glucose and able to be transported out of the cell [1, 2]. After 
approximately 8-12 hours of prolonged fasting, the main source of hepatic glucose output 
switches from glycogenolysis to gluconeogenesis where amino acids, free fatty acids, and other 
fuel sources are used to synthesize glucose, still under the control of glucagon [2, 25]. Through 
the conversion of these fuel sources into pyruvate, oxaloacetate can then be formed and 
converted into phosphoenolpyruvate, the first gluconeogenic intermediate which will undergo 
steps that use ATP to form glucose. Insulin is another dominant regulator of glycogenolysis and 
gluconeogenesis in that the presence of insulin, signaling that glucose is in abundance in the 
body/plasma, both gluconeogenesis and glycogenolysis are inhibited [1, 2, 6]. In insulin 
sensitive individuals, when the release of insulin is triggered and binding of insulin to the insulin 
receptor on the hepatocyte membrane is accomplished, glucose is drawn into the cell to form 
glycogen and the formation of gluconeogenic precursors is inhibited [6]. Together, these 3 
sources of circulating glucose allow for continued euglycemia in the fasting state when all other 
conditions inside the body are normal.  
 Insulin Signaling 
 The intricacies involved in the molecular aspect of insulin signaling is complex, beginning 
with the binding of insulin to its receptor at the cell membrane and activating a cascade of 
effects. When the release of insulin by the pancreatic β-cell is stimulated by an increase in 
blood glucose or by incretins, it signals the skeletal muscle and liver to 1) stimulate the uptake 
of glucose and 2) promote the formation of glycogen (glycogenesis) and halt gluconeogenesis 
by inhibiting the action of glucagon specifically on the liver [1]. Insulin does this by binding to 
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its tetrameric tyrosine-kinase Insulin Receptor (IR) where it becomes autophosphorylated, 
stimulating the phosphorylation of members of the Insulin Receptor Substrate (IRS) subfamily 
[6, 25]. Specifically, IRS-1 will physically interact with the p85 domain of Phosphatidylinositol-3’-
Kinase (PI3K) immediately after it becomes tyrosine phosphorylated by IR, which then activates 
many downstream proteins, perhaps most importantly, Akt or Protein Kinase B (PKB) [6, 7, 22, 
23]. The cascade of phosphorylation events through Akt allows for the exocytosis of Glucose 
Transporter (GLUT2 in the liver, GLUT4 in muscle and adipose tissue) from vessicles to 
subsequent translocation to the cell surface, allowing for the uptake of glucose into the cell [2, 
6]. Simultaneously, Akt will phosphorylate Glycogen Synthase Kinase-3 (GSK3), effectively 
inactivating it and decreasing the rate of phosphorylation of Glycogen Synthase (GS), allowing 
for the synthesis of glycogen [6, 25]. Lastly, the binding of insulin to IR stimulates fatty-acid 
synthesis rather than degradation by activating various transcription factors such as Sterol 
Regulatory Element-Binding Protein 1 (SREBP-1) and enzymes including Acetyl CoA Carboxylase 
(ACC) and Fatty Acid Synthase (FAS) [3, 6]. Another protein important in hepatic insulin 
signaling is cAMP-Responsive Element Binding Protein (CREB) as it further controls hepatic 
glucose production (Summarized in Figure 2) [52, 54]. CREB is most important in the fasted 
state where the cyclic AMP (cAMP) family of proteins become activated by the binding of 
glucagon to the glucagon receptor and ultimately upregulate the phosphorylation of CREB, a 
transcription factor that activates the transcription of gluconeogenic enzyme G6Pase and 
Phosphoenolpyruvate Carboxykinase (PEPCK) [54, 55, 56, 57]. Insulin will also inhibit the 
transcription of certain gluconeogenic enzymes, mainly PEPCK and G6Pase by nuclear exclusion 
of the transcription factor Forkhead Box Protein O1 (FOXO1) [25, 26]. In conclusion, insulin 
sensitivity at the peripheral (muscle) and hepatic level allow for proper insulin signaling 
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resulting in glucose uptake through glucose transporters, fatty-acid synthesis through SREBP-1, 
and gluconeogenic enzyme suppression by FOXO1.  
 
Figure 2: Insulin Signaling Network in Insulin Sensitive Individuals. Insulin signaling cascade, 
beginning with the binding of insulin to the Insulin Receptor at the plasma membrane, triggers a 
phosphorylation cascade that ultimately results in upregulation of glycogen synthesis, inhibition of 
gluconeogenesis, and upregulation of lipid synthesis along with GLUT translocation to plasma membrane 
and glucose uptake (adapted from Saltiel et al., 2001 [6]). 
 
Type 2 Diabetes (T2D) 
 As of 2012, globally, diabetes affected 371 million people, 50% of which continued to be 
undiagnosed [10]. What’s more, the number of people across the world with diabetes is 
expected to rise to almost 440 million people by the year 2030. [11]. Here in the United States, 
according to the Center for Disease Control and Prevention (CDC), an estimated 25.8 million 
people, or 8.3% of the United States, has diabetes, 7 million of which were undiagnosed [12, 
15]. Of all of the people with diabetes in the United States and across the world, 90-95% of 
them have type 2 diabetes [12, 13, 14]. Type 2 diabetes accounts for approximately 12-15% of 
all healthcare expenditures across the globe and has been a causative factor (if not the only 
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causative factor) in almost 250,000 US deaths [12, 14]. The global epidemic that is type 2 
diabetes threatens to substantially worsen within the next 2 decades making the study of and 
prevention of this multi-faceted disease at the forefront of scientific interest today [13]. 
 Type 2 diabetes, also known as “non-insulin dependent diabetes mellitus” or “adult-
onset diabetes,” is a complex disease defined by insulin resistance/impaired insulin sensitivity 
due to impaired β-cell function and failure of target tissues to respond to secreted insulin [12, 
14]. These defects result in constant hyperglycemia because of impaired glucose tolerance 
(IGT) and glucose utilization, increase in hepatic glucose production, dysregulation of insulin 
signaling, and an increase in circulating free fatty acids [13, 14]. Mechanistically, insulin 
resistance, considered a central problem in T2D, occurs beyond the Insulin Receptor (IR) in 
cells, as tyrosine phosphorylation of IR in type 2 diabetic patients is unaffected in skeletal 
muscle, the main site of glucose disposal [14, 16]. Instead, insulin-induced phosphorylation of 
IRS-1 and PI3-K, immediately downstream from IR, have been shown to be significantly 
reduced in type 2 diabetic patients with no change in either protein levels. Further, the same 
trend of decreased phosphorylation with no change in protein level was also characterized in 
regards to Akt in type 2 diabetic patient samples [16, 20]. Together, these indicate that defects 
exist in transmitting the phsophorylation signal when insulin binds to IR in the progression of 
type 2 diabetes [14, 16, 20, 21]. These abnormalities in insulin signaling ultimately result in a 
reduction of glucose transporter translocation to the cell surface, leading to a subsequent 
decrease in glucose uptake by the cell and plasma hyperglycemia [14, 19, 20]. Consequently, 
the worsening hyperglycemia (among other things) leads to an increased need for insulin 
production and secretion from the pancreatic β-cell. This sets in motion a vicious cycle of 
hyperglycemia and hyperinsulinemia, 2 well known type 2 diabetic hallmarks. These are in 
addition to the hyperlipidemia that is also present in T2D. However, over time, the β-cell can no 
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longer compensate for the increase in blood glucose levels and insulin secretion eventually 
decreases significantly along with an overall decrease in β-cell mass and increase in β-cell 
apoptosis [12, 14, 17, 18, 24].  
 The liver, another significant factor in the pathogenesis of type 2 diabetes, controls 
glycogenolysis and gluconeogenesis, both being the main source of glucose output in fasted 
conditions. Glucose homeostasis is significantly skewed when insulin signaling is disrupted 
specifically within the liver, as it results in a failure to suppress HGP and worsened glucose 
intolerance, both found in type 2 diabetes [25, 27, 28]. In fact, excessive HGP from the liver 
positively correlates with fasting hyperglycemia and HGP rates consistently increase with 
increasing hyperglycemia through T2D disease progression [28-31]. Insulin’s direct effect on 
HGP suppression, through binding to its putative receptor on the hepatocyte membrane, is 
severely disrupted in insulin resistant states. Rising plasma hyperinsulinemia due to hepatic 
insulin resistance further contributes to continued glucose output by the liver and 
compentsatory hyperglycemia [6, 28, 29, 30]. When insulin does not bind specifically to its 
hepatic IR because of decreased sensitivity, phosphorylation of IRS-1, PI3-K, and Akt does not 
occur, ultimately resulting in GSK-3 activation, glycogenolysis will occur, and FOXO1 will be 
allowed to enter the nucleus to transcribe gluconeogenic enzymes [6, 25, 26]. Furthermore, 
Michael et al. discovered that when hepatic insulin resistance is modeled where insulin is made 
unable to bind to hepatic IR, mRNA expression of both G6Pase and PEPCK are significantly 
increased, indicating that HGP is highly upregulated [27]. The same group also reported that 
this insulin resistance, studied in liver-specific IR knockout mice, promotes overall 
hyperinsulinemia by simultaneously decreasing insulin clearance while also increasing insulin 
secretion [27].  
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Discovery of PANcreatic-DERived Factor (PANDER) 
 PANcreatic-DERived Factor (PANDER) was initally discovered in 2002 during a screen for 
new cytokines using an Ostensible Recognition of Folds (ORF) algorithm. This algorithm uses 
comparisons, such as known cytokines to an unknown sequence, to determine a protein’s 
predicted secondary structure [32, 38]. Using a  database of known sequences, the ORF 
algorithm uses sequence alignment of repetitive and non-repetitive sequences to establish 
proteins that are homologous in their secondary structures [32, 38]. That is, instead of using a 
protein’s amino acid residue sequence, GORII parameters are used to calculate a protein’s 
secondary structure string which is then used in sequence alignment [32, 34, 38]. In the search 
that uncovered PANDER, secondary structure probes from short chain cytokines like interleukin 
(IL)-2, -3, -4, growth hormone, etc. were utilized and the NCBI GenPept Database was used as 
the known library [34]. The 4-helix bundle secondary structure with up-up-down-down topology 
of  these cytokines used as probes has remained highly conserved throughout the course of 
evolution [33, 34]. In addition to the 4-helix bundle and unique topology, 2 disulfide bridges 
linking the 4 helices at conserved cysteine residues are also signature to these cytokines, 
allowing them to be excellent candidates for structure-based studies such as the ORF algorithm 
[34]. A novel family of proteins entitled family with sequence similarity 3 (FAM3) was 
discovered from the ORF search with 4 putative gene members- FAM3A being the first 
discovered, followed by FAM3B, FAM3C, and FAM3D  [34, 35, 36, 37]. All 4 family members 
consist of 224-235 amino acids and share 31.6-53.3% homology between, but no homology to 
known cytokines besides their predicted secondary structures, perhaps indicating the discovery 
of a novel cytokine subfamily [34, 39]. FAM3B, the second of the 4 genes discovered, is the 
longest FAM3 family member at 235 amino acids long and was later renamed “PANDER” 
because of its robust mRNA expression within the endocrine pancreas determined by northern 
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blot [34, 44]. PANDER mRNA is also expressed to lesser extents within the small intestine and 
prostate [34].  
 
Newly Discovered Structure of PANDER 
 In early 2013, the three-dimensional crystal structure of murine PANDER was elucidated 
using sulfur singular anomalous dispersion (S-SAD) and X-ray data [40]. Johansson et al. 
showed using two different constructs of murine recombinant PANDER, unglycosylated (S)E30 
PANDER and a truncated S46 PANDER, that 1) PANDER is, in fact, not a protein made of all α-
helices and 2) its protein structure displays a globular β-β-α fold made of 2 anti-parallel β-
sheets and a single layer of 3 short α-helices (Figure 3) [40]. Composed of 9 strands in total, 
the first β-sheet contains 4 strands, leaving 5 strands in the second β-sheet, creating a 
completely hydrophobic core within the protein structure [40]. The N-terminal tail of PANDER 
contains the disulfide bridges between cysteine residues that was initially believed to be at 
positions 63-69 and at positions 91-229 in the previous 4-helix model, but is in actuality at 
positions 63-91 and 69-229 [40, 43]. PANDER’s N-terminus also contains the signal peptide in 
the first 30 amino acid residues, followed by the next 29 residues being hidden within the 
protein itself though they, along with the structural integrity of the β-β-α fold are essential to 
PANDER’s overall functionality [40]. These new findings further contradict initial structure-
function studies of PANDER which revealed that truncation of the entire N-terminus had no 
effect on PANDER function and action [43]. PANDER’s new structure also revealed a highly 
conserved 4 water molecule-filled cavity that rests between the 2 β-sheets and has been shown 
to contribute to relative thermal stability of PANDER overall, contrary to evidence that such 
internal protein packing substantially destabilizes proteins [40, 42].   
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Figure 3: Secondary and Crystal Structure of PANDER. This figure illustrates the ribbon secondary 
structure (Left) of FAM3B (PANDER) depicting β-sheets in light blue with α-helices in purple (enhanced 
from Protein DataBase: 2YOQ) and the globular crystal structure form (Right) of the FAM3B protein (also 
adapted from PDB: 2YOQ) [40]. 
 
 Perhaps the most telling feature of PANDER is that it bears no resemblance to not only 
other cytokines that were utilized in its discovery nor to its previously hypothesized 4-helix 
bundle structure, but also to any known protein. In fact, the protein that possesses the highest 
similarity to PANDER was Top7, a novel artificial protein that was specifically created to assess 
the boundaries of realizable proteins structures [40, 41]. Given that there are currently no 
known biological proteins that remotely share the same structure as PANDER, this is indication 
that PANDER could potentially represent a brand new structural class of signaling molecules 
with unique functions [40, 41].  
 
Genomic Structure of PANDER 
 Initial characterization of PANDER in 2002 revealed that, genomically, human PANDER is 
present on chromosome 21q22 with a total of 8 exons over a 40 kb region and murine PANDER 
is located on chromosome 16B5-C4 [34, 45]. A typical signal peptide was also discovered both 
in the murine and human form of PANDER on the N-terminus with a hydrophobic leader 
sequence, indicating targeting to the endoplasmic reticulum (ER) for secretion from the cell [34, 
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52]. This processing of PANDER gives rise to a 23 kDa secreted PANDER product as opposed to 
the full-length 235 amino acid protein at 26 kDa, both detected in cell lysate and media from 
hepatocytes and β-TC3 cells infected with PANDER [34, 44, 52, 67]. Using the 5’- RNA Ligase 
Mediated-Rapid Amplification of cDNA Ends (RLM RACE) method, the PANDER transcriptional 
start site in insulin-producing pancreatic β-TC3 cells was identified 520 bp upstream from the 
translational start codon [45, 63]. Within the 5’ flanking region of the PANDER gene at positions 
-99 and -48 uptream of the transcriptional start site are 2 TATA boxes and 3 A-box and E-box 
elements each from -335 to +491 bp, indicating a potential responsiveness of the PANDER 
promoter to glucose, much like that of the insulin promoter [45, 48]. Additionally, hepatocyte 
nuclear factor (HNF) 1 and 4, octamer binding protein-1 (Oct-1), and signal transducer and 
activator of transcription (STAT) 3, 5, and 6 binding sites were identified, indicating islet-
specificity [45]. HNF-1 and HNF-4, though normal in the pancreas, regulate hepatocyte 
transcription and indicate expression within liver-derived cell lines as well, verified by an 
increase in PANDER promoter activity in BNL-CL2 liver-derived cell lines [45, 62]. In summary, 
the 5’ untranslated region (5’ UTR) of the PANDER gene contains not only the PANDER 
promoter and transcriptional start site, but all of the putative transcriptional factor binding sites 
that potentially give PANDER its tissue-specificity and nutrient responsiveness [34, 45, 49].  
 
Regulation of PANDER Transcription 
 Following the lead of other various islet-specific proteins like insulin and glucagon 
mentioned previously, dominant control of their expression is exhibited at the transcriptional 
level by promoter elements and nutrient responsiveness [45, 46, 47]. This led to the further 
characterization of the regulatory regions and the islet-specific transcriptional elements that 
control PANDER expression at the transcriptional level. 
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 First, Burkhardt et al. reported that the minimal element required for maximal promoter 
activity and PANDER gene expression happens to be in the +200/+491 region where all 3 E-box 
elements and a single A-box lie [45, 49]. Further, given that the PANDER promoter contains 
several E- and A-box elements and therefore could potentially be stimulated by glucose, glucose 
stimulation experiments were performed using various constructs of the PANDER promoter 
containing a number of those elements [45]. It was reported that the PANDER promoter was 
significantly upregulated by glucose in a dose-dependent manner and that treatment of β-TC3 
cells with 22 mM D-glucose had the biggest increase in promoter activity when using luciferase 
plasmids under the control of the PANDER promoter [45]. This significant response of the 
promoter to glucose was also observed in murine pancreatic islets that were transfected with 
luciferase/PANDER plasmids but not in α-TC3 cells that secrete glucagon, indicating cell-type 
and nutrient specific expression of PANDER [45, 52]. The mechanism of the PANDER promoter’s 
glucose responsiveness was found to be due to CREB-dependent pathway involving Ca2+, and 
either PKA or PKC where CREB phosphorylation was increased as well as PANDER gene 
expression in response to glucose [52, 65]. 
 Cell-specificity was further conformed when cis elements within the promoter, A-boxes 
specifically, proved to be essential for binding an important transcription factor in pancreatic 
development, Pancreatic/Duodenal Homeobox-1 (PDX-1) [49, 50, 52]. Using chromatin 
immunoprecipitation (ChIP) and electromobility shift assay (EMSA), Burkhardt et al. showed 
that PDX-1 binds to all 3 of the A-boxes in the PANDER promoter in the -338 to +491 region 
and site directed mutagenesis of the 2 A-boxes in the -100 to +491 region completely 
deteriorated PANDER promoter activity  [49, 52]. The same 2 A-boxes proved to be critical in 
the PANDER promoter’s glucose responsiveness as their combined mutagenesis markedly 
reduced promoter activity [49, 52]. Additionally, 2 more β-cell specific transcription factors, V-
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maf musculoaponeurotic fibrosarcoma oncogene homolog A (MafA) and β-cell E box 
Transactivator 2/NeuroD (BETA2/NeuroD) significantly upregulated activity of the PANDER 
promoter when combined with PDX-1, though PDX-1 alone had the greatest effect [49, 52, 64]. 
As a whole, PANDER transcription is regulated by β-cell specific transcription factors that bind to 
elements within the PANDER promoter and enhance promoter response to glucose stmulation, 
among other nutrients. 
 
Regulation of PANDER Secretion 
 Just as PANDER transcription was enhanced by glucose, PANDER secretion has also 
been shown to be upregulated by glucose, for one. PANDER has been reported to  co-localize 
with insulin in secretory granules of β-cells as shown by immunogold-labeling electron 
microscopy, and not only did glucose induce PANDER mRNA and protein expression in β-cells 
and islets,  but it also increased PANDER secretion dose-dependently from β-cells almost 3-fold 
[52, 65, 66, 68]. The same effect was observed when PANDER was overexpressed in murine 
islets [66]. Interestingly, PANDER secretion from β-cells positively correlated with glucose-
stimulated insulin secretion (GSIS) from the same cells, indicating the possibility that PANDER is 
likely co-secreted with insulin [66].  
 PANDER was also observed to be secreted from pancreatic α-cells, though secretion was 
not upregulated by increasing to decreasing glucose stimulation [52, 66, 69]. Carnegie et al. 
first reported that PANDER was present in pancreatic α-TC1-6 cells in granular cytoplasmic 
compartments and does not co-localize with glucagon [52, 69]. However, when stimulated with 
L-Arginine, the most robust known stimulator of glucagon secretion, PANDER secretion 
increased from α-TC1-6 cells significantly at up to 20 mM treatment in addition to a significant 
increase in glucagon secretion [52, 69, 70, 71]. What’s more, when treated with low 
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concentrations of insulin (17 nM) alone or in combination with L-Arginine, PANDER secretion 
from α-TC1-6 cells was significantly increased (moreso when treated with insulin alone), while 
still allowing for insulin-induced glucagon suppression [52, 69]. The mechanism for the 
unexpected upregulation of PANDER secretion from α-TC1-6 cells in response to insulin was 
reported to be attributed to the PI3K-Akt node of insulin signaling [69]. In general, PANDER is 
present in and secreted from pancreatic islets, α-cells, and β-cells in response to a variety of 
nutrient stimuli including glucose in β-cells and L-Arginine and insulin in α-cells, indicating a 
potential role for PANDER in glucose homeostasis functioning in glucoregulatory mechanisms 
[52]. 
 
Summary of PANDER Animal Models 
 Characterization of PANDER in-vivo has only recently begun within the past 3 years with 
numerous PANDER animal models being created. Not only are there PANDER knockout models, 
but also siRNA PANDER knockdown models, adenovirus-PANDER overexpressing models, and a 
recently characterized PANDER transgenic model to contribute to the characterization of 
PANDER’s biological role in-vivo. 
 Hepatic Ad-PANDER Overexpressor and siRNA Knockdown 
 Li et al. developed a hepatic PANDER overexpressor by injecting adenoviral-PANDER 
(ad-PANDER) into the tail of C57BL/6 mice targeted for the liver [51, 62]. This hepatic-specific 
PANDER overexpression increased significantly increased hepatic steatosis with an increase in 
triglycerides within the serum and upregulation in both mRNA and protein expression of lipid 
metabolism genes including SREBP-1, FAS, and peroxisome proliferator-activated receptor γ 
(PPARγ) [51, 52, 62]. In addition, plasma insulin levels were increased with disruption of 
phosphorylation of proteins in the hepatic insulin signaling cascade, specifically Akt, 5’ 
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adenosine monophosphate-activated protein kinase (AMPK), and the transcription factor 
FOXO1, though unphosphorylated FOXO1 expression was the most markedly increased [51, 
62]. Small-interfering RNA (siRNA) knockdown of hepatic PANDER was reported by the same 
group to reverse all of the above affects, but in db/db mice, a mouse strain used to model type 
2 diabetes, not C57BL/6 mice [51, 52, 53]. Hepatic PANDER silencing also significantly reduced 
blood glucose levels and improved insulin resistance by decreasing expression of gluconeogenic 
enzymes and increasing phosphorylation of both Akt and AMPK while reducing the expression of 
FOXO1 [51, 52, 62]. Taken together, these ad-PANDER and siRNA knockdown models suggest 
that PANDER induces hepatic lipogenesis and insulin resistance primarily through a FOXO1 
dependent pathway where PANDER decreases the phosphorylation of key insulin signaling 
proteins to aid in the increase in FOXO1 [51, 62].  
 Ad-PANDER Overexpressor 
 Wilson et al. also created a serum PANDER overexpressor using adenoviral gene delivery 
into the tail vein of male C57BL/6 mice [52, 54, 62]. This ad-PANDER model presented with 
increased fasting blood glucose levels and the compensatory hyperinsulinemia due primarily to 
elevated levels of corticosterone (murine glucocorticoids) and not glucagon, glycogen, or any 
other factor [52, 54]. Corticosterones/glucocorticoids have been shown to be present in higher 
concentrations in type 2 diabetic obese models and are reported to increase blood glucose 
levels through increasing gluconeogenesis and perpetuate insulin resistance in vivo [52, 54, 58, 
59]. Ad-PANDER mice were also shown to be glucose intolerant during a glucose tolerance test 
(GTT), the result of the fasting hyperglycemia, as the mice were peripherally insulin sensitive 
[54, 62]. Further, PANDER overexpression in these C57BL/6 mice after an overnight fast and 
after being refed for 4-hours following an overnight fast resulted in an increase in mRNA 
expression of G6Pase and PEPCK, though only significant without being refed [52, 54, 62]. 
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There was also no observed effect on the phosphorylation of Akt or GSK3 levels in the ad-
PANDER mice, with the ad-PANDER mice revealing a decrease in liver triglycerides, contrary to 
the previously mentioned ad-PANDER murine model [51, 54]. In all, this specific ad-PANDER 
model suggests a role for PANDER as a causative agent of hyperglycemia in glucose 
homeostasis in the fasting state, by upregulating HGP through gluconeogenesis and increasing 
corticosterone levels [52, 54]. 
 PANDER Transgenic Overexpressor 
 A PANDER transgenic (PANTG) mouse was created to specifically overexpress PANDER 
in the pancreas, specifically in the islets, using a portion of the PDX-1 promoter in B6SJLF1/J 
mice [50, 80, 81, 82, 96]. These mice initially presented with decreased β-cell mass and glucose 
intolerance on HFD, mimicking that of a type 2 diabetic model [80]. Further characterization of 
these PANTG mice using hyperinsulinemic-euglycemic clamp (HEC) studies which revealed a 
similar glucose disposal rate and peripheral sensitivity on both a HFD and normal chow 
compared to WT, but a significant increase in HGP and decrease in % HGP suppression, 
indicating insulin resistance at the hepatic level in PANTG mice [81]. These mice also presented 
with significantly higher fasting glycemia compared to WT mice in addition to glucose 
intolerance previous observed and an increase in overall weight gain [82, 96]. Mechanistically, 
the PANTG mice displayed a decrease in phosphorylation of AMPK previously shown in an ad-
PANDER acute model with consequential hepatic hyperlipidemia [51, 82, 96]. This first 
genomically overexpressing PANDER murine model further supports PANDER’s proposed 
enhancement of glucose intolerance and insulin insensitivity in-vivo. 
 PANDER Knockout Model 
 Lastly, in contrast to siRNA knockdown PANDER murine model, Cooperman et al. 
generated a global PANDER knockout (PANKO) model, devoid of any circulating PANDER, to aid 
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in elucidating PANDER’s biological roles [52, 60, 61, 62]. This mouse, generated by replacing 
the first 2 exons of the PANDER gene including the transcriptional start site with a neomycin 
cassette in the reverse order (Figure 4), was backcrossed onto a C57/129 genetic background 
[60].  
 
Figure 4: PANDER Gene Targeting Strategy. Illustration of the targeting strategy used when 
creating the PANKO mouse, where a region of the PANDER promoter, UTR, transcriptional start site, 
signal peptide, and first 2 exons were replaced with a Neomycin casette in the reverse order. The 
Neomycin gene was flanked by a 4.3 kb and 2.9 kb arm of the PANDER gene, leading to its disruption 
(adapted from Cooperman et al., 2010) [60]. 
  
 In general, the PANKO mouse displayed glucose intolerance during a GTT due to an 
impairment in insulin secretion and abnormal Ca2+ handling within pancreatic islets suggesting 
that PANDER potentially affects calcium homeostasis in response to glucose [52, 60, 62]. 
Insulin levels were also elevated in the PANKO mice during a GTT, due primarily to a decrease 
in insulin clearance within the liver [60]. The increase in insulin levels was accompanied by 
similar levels of other hormones including leptin, c-peptide, glucagon, and amylin [60]. On the 
other hand, the same PANKO mice, under hyperinsulinemic-euglycemic clamp conditions, 
exhibited lower HGP and higher % HGP suppression, indicating a degree of hepatic insulin 
sensitivity compared to wild-type (WT) mice [52, 60, 62]. This is accompanied by a significant 
decrease in expression of G6Pase and PEPCK after an overnight fast and no effect on blood 
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glucose levels [52, 54, 62]. When evaluated on a high-fat diet (HFD) for a 10 week duration, 
the PANKO C57/129J mice presented with significantly lower blood glucose levels after both a 
24 and 48 hour fast and glucose intolerance during GTT [52, 61, 62]. Interestingly, insulin 
levels at all time points during a GTT were lower in PANKO mice compared to WT, where they 
were previously elevated when fed normal chow [60, 61, 62]. Fasting expression of G6Pase and 
PEPCK mRNA remained decreased even when PANKO mice were fed HFD, and overall weight 
along with food consumption were similar [61]. As a whole, it appears that the loss of 
circulating PANDER could act as a protectant against fasting hyperglycemia when being fed a 
HFD for a minimum of 10 weeks by suppressing expression of gluconeogenic enzymes [52, 61, 
62]. 
 
Role of PANDER in Glycemic Regulation 
 In-vitro and in-vivo data regarding PANDER suggest a potential role in glycemic 
regulation, especially its response to nutrient stimulus. Interestingly, under physiological 
conditions of insulin sensitivity and normal glucose tolerance, PANDER promotes these normal 
processes by facilitating the secretion of insulin from β-cells, and insulin, as the dominate 
molecule, will suppress HGP regardless of PANDER’s actions [52, 62]. As evidenced in the 
PANDER murine models summarized above, it is only where there is an excess of PANDER in a 
combination with one or more states of hyperglycemia, hyperinsulinemia, or hyperlipidemia, 
that PANDER begins to exert negative effects on overall glycemic regulation [39, 52, 62]. By 
using a type 2 diabetic murine model, the db/db mouse, where hepatic PANDER expression was 
silenced by siRNA, hepatic lipogenesis, insulin resistance shown by a decrease in 
phosphorylation through the insulin signaling cascade, and fasting hyperglycemia were all 
abolished and enhanced glucose tolerance was restored [51, 62]. Additionally, Wilson et al. 
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corroborated this evidence by measuring the serum PANDER levels in C57BL/6 mice considered 
to be young and lean and observed a decrease in serum PANDER both fed and fasting 
compared to aged, fat mice [54]. These aged, fat mice with natural elevated serum PANDER 
levels also had higher fasting blood glucose levels compared to young, lean mice, further 
indicating that under normal physiological conditions, PANDER will work to maintain normal 
glycemia and HGP [52, 54]. The PANTG mouse model also exhibits fasting hyperglycemia and 
decreased β-cell mass while on a HFD and increased hepatic triglyceride content compared to 
WT proving that increased PANDER works with lipids to promote hyperglycemia whereas in 
normal control mice, this is delayed, or even non-existant [52, 80, 82]. 
 
Role of PANDER in Type 2 Diabetes 
 Type 2 diabetes is generally defined by 3 hallmarks- hyperglycemia, hyperinsulinemia, 
and hyperlipidemia which all exacerbate the progression of the disease. Perhaps the most 
telling data regarding PANDER and its potential pathogenesis in type 2 diabetes is the effect 
that it has on the liver to induce all 3 diabetes hallmarks [62]. Not only does PANDER bind to 
the liver membrane shown through I125 labeling saturation studies, but its binding is highly 
specific though there has been no elucidation of the PANDER receptor [62, 72]. Further, 
treatment of hepatocellular liver carcinoma (HepG2) cells with PANDER inhibited insulin-
stimulated signaling beginning at IR, through Akt, suggesting that PANDER induces hepatic 
insulin resistance [62, 72]. This is in addition to HEC studies on the PANTG corroborating 
evidence that hepatic insulin resistance is induced by PANDER and HGP was upregulated in ad-
PANDER and PANTG models [81]. Hyperglycemia is also driven by PANDER in that not only is 
the PANDER promoter significantly stimulated by high glucose concentrations and HGP is higher 
in-vivo, but PANDER enhances the expression of G6Pase and PEPCK as evidenced through ad-
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PANDER, PANKO models, and hepatocytes treated with PANDER exhibiting higher glucose 
production [45, 49, 52, 54, 61]. The combination of increased HGP in clamp studies and 
increased rate of gluconeogenesis with PANDER murine models having a higher fasting 
glycemia makes PANDER responsible for at least 1 diabetic hallmark- hyperglycemia. 
 Hyperinsulinemia, both a cause and consequence of hyperglycemia, is evident in the 
presence of PANDER as insulin stimulates the PANDER promoter and enhances PANDER 
secretion from α-cells [52, 69]. Hyperinsulinemia, in turn, creates a compensatory increase in 
glycemia through decreased insulin sensitivity and upregulating HGP, further increasing 
PANDER expression and secretion from β cells [52]. Hepatic steatosis, serum triglycerides, and 
expression of lipid metabolic genes are all upregulated in murine models overexpressing 
PANDER in addition to recent evidence claiming that palmitic acid, a long chain fatty acid 
molecule, significantly increases the expression of both PANDER mRNA and protein in murine β 
TC6 cells [51, 52, 90]. This signifies that not only does PANDER enhance circulating and hepatic 
hyperlipidemia, but it also promotes further hyperlipidemia. Taken together, all of the hallmarks 
that define T2D also define an increase in PANDER expression, secretion, and action, ultimately 
creating a vicious cycle of T2D initiation and progression aided by increased PANDER levels. 
This makes PANDER an attractive therapeutic drug target in the treatment of T2D to slow or 
even prevent the onset and progression of the metabolic abnormalities associated with T2D and 
restore glucose tolerance and insulin sensitivity [52, 62]. 
 
Role of PANDER in Cancer 
 Most recently, within the last year, PANDER has evolved to be a topic of interest of the 
realm of cancer research. PANDER was recently discovered in a number of human cancer cells 
including human hepatocellular carcinoma cells, lung carcinoma cells, and even human colon 
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cancer cells [75]. Interestingly, RNA interference (RNAi) experiments to silence PANDER 
expression resulted in apoptotic cell death of both human colon cancer cells and lung carcinoma 
cells, whereas the earliest PANDER experiments revealed that PANDER overexpression or 
treatment induced apoptosis of β-cells through the CDKN1A/caspase-3 network [43, 44, 67, 75, 
76]. The silencing of PANDER by RNAi that subsequently lead to apoptosis in cancer cells was 
shown to be mediated by tumor protein 53 (p53), as it was significantly upregulated following 
PANDER silencing [75]. Further, phosphorylation of p53 was increased when PANDER was 
silenced, and when reversed, when p53 was silenced, PANDER-induced apoptosis was nearly 
completely reversed [75].  
 Down-regulation of PANDER mRNA and protein levels was observed in oral squamous 
cell carcinoma (OSCC) cells and primary patient samples compared to normal oral cells [73]. 
This downregulation of PANDER was attributed to microRNA (miRNA) upregulation in the 3’ UTR 
of the PANDER gene, causing imperfect base pairing [73]. This was the first study that linked 
PANDER expression (down-regulated, in this case) to the carcinogenesis of a specific cancer 
type, oral squamous cell carcinoma, and characterized the cause of downregulation being that 
of miRNA upregulation [73]. A similar downregulation of PANDER expression was also observed 
in human gastric cancer where the lower PANDER mRNA levels in gastric cancer samples 
correlated to greater depth of tumor invasion [74, 77]. Li et al. performed the first studies 
evaluating the effects of the 7 different alternative splicing isoforms of PANDER in colon 
cancers, specifically in 6 colon adenocarcinoma cell lines and tissues [74]. One PANDER isoform, 
a 258 amino acid residue non-secretory form of PANDER (FAM3B-258), was found to be highly 
upregulated in its expression in not only colon cancer cell lines but also colorectal 
adenocarcinoma tissue samples, though tumor differentiation was poor [74]. Overexpression of 
FAM3B-258 in colorectal carcinoma cells was shown to enhance cell invasion and migration 
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through a Slug-dependent pathway, where the transcription factor Slug was highly expressed in 
the cells overexpressing FAM3B-258 [74]. Slug will work with another transcription factor, Snail, 
to downregulate to the expression of cell adhesion molecules and allow for invasion, both of 
which were upregulated in FAM3B-258 overexpression cells [74, 77, 78]. Additionally, FAM3B-
258 enhanced colon cancer metastasis to the lung in nude mice, further confirming that FAM3B-
258 works with Slug to aide in cancer cell invasion and migration [74]. In summary, though 
most research involving PANDER centers around its mechanism of action in glucose 
homeostasis and the pathogenesis of type 2 diabetes, PANDER’s role in up/downregulating 
various cancers is quickly emerging, as well, especially in oral, gastric, and colorectal cancers.  
 
Other FAM3 Family Members 
 When PANDER was discovered in 2002 (known as FAM3B at the time), it was only one 
gene in a family of 4 putative genes including FAM3A, FAM3C, and FAM3D [34]. Though FAM3B 
is arguably the most researched of all 4 genes, research on FAM3A, FAM3C, and FAM3D, 
though minimal, has begun to surface. First, FAM3D was initiall found to be highly expressed in 
the placenta and to a smaller extent in the small intestine, known to be very hyperproliferative, 
indicating that FAM3D could be important in cell proliferation [34]. In 2012, de Wit et al. 
revealed that FAM3D, the human ortholog of murine Oit1, was robustly expressed in the 
gastrointestinal tract of humans and was affected by nutrient stimulus [83]. Levels of FAM3D in 
human plasma was shown to be decreased after fasting, and more interestingly, after being on 
a HFD for 3 weeks, FAM3D levels were elevated postpradially after also being fed a HFD shake 
compared to subjects being on a LFD [83]. FAM3D has also been linked to diabetes melllitus in 
patients suffering with pancreatic adenocarcinoma, but has never been elucidated further [83, 
84]. The expression pattern of FAM3D, though limited in extensive research, is similar to that of 
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PANDER and is affected by nutritional status in a similar manner, specifically in its response to 
HFD. 
 FAM3A, the first gene identified in the ORF algorithm, is composed of 230 amino acid 
residues and is expressed in a wide array of tissues, including the most robust expression in the 
heart, followed by the liver, pancreas, colon, and small intestine, among others [34, 39]. Zhou 
et al. is the only group thus far to report on FAM3A’s activity in the liver, where they 
determined that PPARγ overexpression enhanced FAM3A expression in HepG2 cells which was 
reversed with PPARγ agonists in HepG2 cells and primary hepatocytes [35, 39]. The FAM3A 
promoter was also highly activated by PPARγ and and PPARγ was shown to bind directly to its 
putative binding site in the FAM3A promoter, the peroxisome proliferator response element 
(PPRE) [35, 85]. Site-directed mutagenesis of PPRE deteriorated FAM3A’s promoter response to 
PPARγ and in-vivo, the upregulation of the FAM3A promoter resulted in an increased 
phosphorylation of Akt [35]. Like that of PANDER and FAM3D, FAM3A evidence suggests a 
potential role in controlling hepatic lipogenesis through PPARγ and further control hepatic 
metabolism [35, 39]. 
 FAM3C, also known as interleukin-like epithelial-mesenchymal transition (EMT) inducer 
(ILEI), as its name suggests, is integral in the process of EMT and breast cancer progression, 
much different than that of its other family members [40, 86]. Initial reports on FAM3C 
centered around its robust expression in the ear and the laminar retina, where it where it was 
identified as perhaps inducing nonsyndromic hearing loss [36, 37, 40, 86, 87]. FAM3C’s name 
was changed to ILEI after Waerner et al. discovered that it was a molecule involved in EMT, 
where epithelial cells’ transition to cancer begins, as evidenced in its altered expression and 
correlation to tumor metastasis [40, 86]. ILEI is expressed to its highest levels in the process of 
EMT and overexpression of ILEI exclusively in mammary epithelial cells promotes EMT and 
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tumor metastasis of the cells [86]. Further, transforming growth factor-β (TGF-β), a known EMT 
inductor, will enhance the activation of ILEI by inhibiting the action of heterogeneous nuclear 
ribonucleoprotein E1 (hnRNP E1) and TGF-β activated translation (BAT) element that work to 
suppress ILEI translation [40, 88, 89]. Through this TGF-β activation of ILEI, and conformation 
of ILEI’s role in EMT shown through siRNA silencing, EMT progresses and the expression of ILEI 
(especially in the cytoplasm) correlates positively with breast cancer patient outcome [40, 88, 
89]. FAM3C is the first member of the FAM3 family to have a suggested role in the progression 
of cancer, while FAM3A and FAM3D relate to PANDER in their roles in maintaining metabolic 
homeostasis. Nevertheless, the family with sequence similarity 3 has proven to be an integral 
part of normal human processes and all members have implications in the pathogensis of 
diseases including cancer and type 2 diabetes mellitus. 
 
Project Summary and Specific Aims 
Type 2 diabetes (T2D), a disease affecting 371 million people around the world as of 
2012, is expected to reach that of epidemic proportions by affecting just over 440 million people 
by the year 2030 [10, 11]. The effects that T2D has taken and has yet to take globally, 
nationally, and economically greatly exacerbate the need to further understand proteins 
involved in insulin signaling, their regulation, and how they contribute to the onset and 
progression of the disease. Pancreatic-Derived Factor, or PANDER, is a novel protein hormone 
discovered in 2002 that was shown to be highly expressed within pancreatic islets, co-secreted 
with insulin, and stimulated by glucose [34, 66]. For these reasons, in addition to the fact that 
PANDER binds to the liver membrane and inhibits the activation of critical insulin-signaling 
molecules, it is believed that PANDER plays a role in glucose homeostasis [72]. Initial acute 
murine studies show that C57BL/6 mice overexpressing PANDER hepatically exhibit impaired 
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glucose tolerance, elevated gluconeogenic gene expression, and increased hepatic lipogenesis 
[51, 54]. However, previous studies of PANDER knockout mice on a mixed genetic C57/129J 
background also revealed glucose intolerance, similar insulin sensitivity to WT, impaired insulin 
secretion from pancreatic β-cells, yet reduced mRNA expression of gluconeogenic enzymes [54, 
60]. These results are further convoluted by a single report claiming knockdown of PANDER 
resulted in an attenuation in hepatic steatosis, insulin resistance, and hyperglycemia [51].These 
novel contradictory findings further emphasize the importance of understanding PANDER’s role 
in glucose homeostasis and hepatic insulin signaling in a genetically pure animal knockout 
model. 
The following project being proposed will aim to determine the phenotype of the 
PANKO-C57 PANDER knockout mouse in addition to elucidating the mechanism of selective 
hepatic insulin resistance caused by PANDER shown in previous in-vivo and in-vitro data. 
Previous in-vivo studies have not provided a clear mechanism of PANDER’s action in a pure-
bred C57BL/6J murine model and therefore have reported conflicting results. Ultimately, by 
characterizing a PANDER knockout mouse on C57BL/6J background, perhaps one of the best 
understandings of how PANDER affects central cellular metabolic processes and its implications 
in type 2 diabetes will be uncovered. Based on in-vitro data and initial characterization of the 
PANKO mouse on C57/129J mixed genetic background, we hypothesize that the PANKO-C57 
mice will exhibit improved glucose tolerance and insulin sensitivity with enhanced hepatic insulin 
signaling. The specific aims to test this hypothesis are as follows: 
Specific Aim 1: Determine the overall glycemic regulation and metabolic characterization in the 
pure PANKO-C57BL/6 mouse 
 1.1: Determine fasting glycemia, hormonal, and plasma triglyceride differences 
 between PANKO-C57 mice and WT mice 
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 1.2: Characterize post-prandial differences between PANKO-C57 and WT mice  via 
 glucose and insulin tolerance testing 
Specific Aim 2: Elucidate the mechanism of PANDER in hepatic signaling 
 2.1: Characterize the impact of PANDER on the PI3Kinase-Akt node of hepatic 
 signaling  
 2.2: Determine the expression of gluconeogenic enzymes G6Pase and PEPCK 
 2.3: Measure differences in hepatic glycogen content and hepatic triglyceride 
 content 
  
28 
 
 
 
 
 
 
CHAPTER TWO: INITIAL PHENOTYPING OF PANDER KNOCKOUT C57BL/6 MOUSE 
 
Rationale 
 As presented previously, PANDER animal models, both transgenic and knockouts to 
date, have provided confounding evidence in terms of PANDER and its role in glycemic 
regulation, as a number of the models are acute. Transgenic mice overexpressing PANDER 
present with overall higher blood glucose levels and impaired hepatic insulin signaling at Akt 
[51, 54]. siRNA mediated knockdown of PANDER has been shown to enhance insulin signaling 
at the PI3K-Akt node in addition to decreasing hepatic lipogenesis [51]. However, a single 
report regarding a generated PANDER knockout mouse suggested glucose intolerance with a 
lower HGP and decreased expression of gluconeogenic enzymes, but this animal, though not 
acute, was on a genetically mixed C57/129 background, not optimal for phenotypic 
characterization [54, 60]. Compilation of discordant in-vivo data regarding PANDER begs a 
knockout model on a purebred C57BL/6 background for complete characterization and novel 
findings as to PANDER’s complete role in-vivo [52].  
 The C57/129 PANKO mouse, after its standard initial characterization, was subsequently 
backcrossed for 8 generations onto the C57BL/6 background to allow for optimal phenotypic 
characterization, as C57BL/6 mice are the most widely used inbred mouse strain in scientific 
studies [91, 92]. This resulting congenic PANKO strain, after a total of 10 generations of 
backcrossing, ended up being approximately 99.9% homozygous at the specific affected null 
locus to any additional PANKO mice born, ensuring no interference from a mixed genetic 
background in phenotyping [91]. Once backcrossed on to C57BL/6 background, the mice were 
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backcrossed an additional generation at The Jackson Laboratory (Bar Harbor, ME) where they 
were submitted under strain name B6.129S6-Fam3btm1Bkht/J for maintenance before being 
shipped to Moffitt Cancer Center’s Stabile Vivarium (Tampa, FL). The mice were further 
backcrossed one more additional generation upon arrival at Moffitt Cancer Center for murine 
colony derivation, allowing for the optimal 10 generation backcross on to the C57BL/6 
background for maximum homozygosity in the colony [91]. 
 By utilizing this PANDER knockout model on a C57BL/6 background, we hypothesized 
that the PANKO-C57 mouse would exhibit enhanced glucose tolerance complemented with an 
increase in insulin sensitivity shown through metabolic tests with lower fasting glycemia and 
hormonal levels to be evaluated using high-sensitivity assays [60].  
 
Experimental Design & Methods 
 Murine Colony Acquisition, Care, and Maintenance 
 3 PANKO-C57 and 5 total C57BL/6 breeding pairs were obtained from Jackson 
Laboratory (Bar Harbor, ME) after being backcrossed an additional generation and genotype 
confirmed for animal husbandry and colony start-up. The mice were maintained in standard 
breeding cages with standard pellet bedding at Moffitt Cancer Center’s Stabile Vivarium 
(Tampa, FL) given normal chow (Purina®) ad-libitum with constant access to water in 
accordance with approved breeding Institutional Animal Care and Use Committee (IACUC) 
protocol 4005 M. Any pups born were weaned at 3-4 weeks of age before being ear-tagged for 
identification and tail-snipped for DNA genotyping. Mice were then subsequently transferred to 
the approved Research protocol (4071 R) for experimentation. All maintenance and procedures 
conducted adhered to approved IACUC protocols at the University of South Florida and Moffitt 
Cancer Center (Appendix B & C).  
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 Murine DNA Genotyping 
 DNA was extracted from all PANKO-C57 and WT pups at  3-4 weeks of age for 
conformation of respective genotype. 0.5 centimeter long tail snips were obtained from each 
mouse using a single edge razor blade (Fisher Scientific, Pittsburgh, PA). Tails snips were 
subsequently placed in Eppendorf tubes (Hauppauge, NY) with volumes indicated of Buffer ATL 
and Proteinase K at 56°C overnight for tail dissolving according to manufacturer’s protocol in 
DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA). DNA isolation was further completed 
according to manufacturer’s protocol and concentrations/purities were determined using a 
Nanodrop (Thermo Scientific, Wilmington, DE). Eluted DNA samples were used in PCR 
amplification under standard cycling conditions where each sample was amplified using WT 
primers (-338 Kpn and -35 TA) and KO primers (-338 Kpn and KONeoP2) to confirm no 
heterozygous mice were present [45, 60]. DNA samples were subsequently run in a 1% 
agarose gel with 2 μl ethidium bromide for DNA visualization. Gels were visualized using Fuji 
LAS4000 imager (FujiFilm GE Healthcare, Pittsburgh, PA) and genotype was confirmed through 
presence of specific banding patterns base on WT (approx. 850-1000 bp) or KO (approx. 400-
500 bp) primers used and compared to a standard 1 Kb Plus DNA Ladder (Invitrogen, Carlsbad, 
CA).  
 Measurement of Fasting Glycemia 
 4-5 month old male and female PANKO-C57 and WT C57BL/6 mice were fasted 
overnight (>16 hours, long-term) by removal of all food, leaving water, for blood glucose 
reading after the overnight fast. The same procedure was followed when short-term fasting 
glycemia was measured where male and female PANKO-C57 and WT mice were fasted for 4 
hours by removal of food from cages. A TRUEtrack blood glucose meter (Walgreens) with 
respective strips was utilized to evaluate the glucose content of approximately 1 μl of blood 
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obtained via a tail vein puncture using a sterile lancet. All values and concentrations were 
analyzed via GraphPad Prizm (Version 5) and statistical significance (p<0.05) between KO and 
WT was determined using 2-tailed Student t-test. 
 Body Weight Measurements 
 Body weights of PANKO-C57 and WT mice were measured (Beckman Digital Scale) in 
the mornings after feeding normal chow ad-libitum in 2-3 week increments. Weight 
measurements began at 8 weeks of age after being weaned and continued to 21-23 weeks of 
age. All weights were measured in grams and were analyzed by the mean and SEM for each 
group at each time point weight was measured. All weights were analyzed via GraphPad Prizm 
(Version 5) and statistical significance (p<0.05) between KO and WT was determined using 2-
tailed Student t-test. 
 Measurement of Hormonal Analytes 
 Evaluation of hormonal differences was conducted using a MAGPIX® Luminex (Austin, 
TX) Multiplexing Instrument and plasma (Figure 5). Blood was obtained via a submandibular 
vein poke from male PANKO-C57 mice at 2 months and 5 months of age along with WT male 
mice of the same ages using 18-gauge PrecisionGlide needles (BD Diagnostics, Franklin Lakes, 
NJ) and microvette tubes. Samples were kept on ice until processing. Samples were then 
centrifuged for 10 minutes at 13.2 rpm for plasma separation, the plasma supernatant removed 
and placed in an Eppendorf (Hauppauge, NY) tube, then stored at -80°C until use. The 
MAGPIX® panel that was used included antibody-immobilized beads for the following analytes: 
Amylin, Resistin, Glucagon, Insulin, C-Peptide, and Leptin. The assay was conducted using 
approximately 10-30 μl of fasting plasma used in triplicate in accordance with the 
manufacturer’s protocol for the Mouse Metabolic Magnetic Bead Panel (Millipore, Billerica, MA). 
Results were then analyzed based on a Mouse Metabolic Hormone Standard provided with the 
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assay kit, using WT C57BL/6 plasma as a control, and xPONENT® data analysis system 
(Luminex). All values and concentrations were analyzed via GraphPad Prizm (Version 5) and 
statistical significance (p<0.05) between KO and WT was determined using 2-tailed Student t-
test.  
 
Figure 5: Luminex Multiplexing Concept & Protocol. This figure represents the concepts and 2-day 
protocol involved in the MAGPIX® Luminex system, beginning with conjugation of the serum sample 
added to the plate to the immobilized magnetic beads. Steps 2 and 3 are completed before quantitative 
measurement in Step 4 using xPONENT® analysis. 
  
 Measurement of Plasma Corticosterones 
 Corticosterone levels were measured longitudinally in serum from male PANKO-C57 and 
WT mice at 2 and 5 months of age after an overnight fast. Serum was obtained from mice as 
described above in Measurement of Hormonal Analytes. Corticosterone ELISA assay was 
performed according to manufacturer’s protocol provided in the ENZO® Life Sciences 
Corticosterone ELISA Kit (ADI-900-097) (Farmingdale, NY). Results were obtained via VersaMax 
Microplate Reader (Molecular Devices, Sunnyvale, CA) with SoftMax® Pro software at a 
wavelength of 405 nm for optimal absorbance according to assay protocol. All values and 
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concentrations, presented in ng/mL, were analyzed via GraphPad Prizm (Version 5) and 
statistical significance (p<0.05) between KO and WT was determined using 2-tailed Student t-
test. 
 Measurement of Plasma Triglycerides 
 Plasma triglyceride content was evaluated by adhering to the manufacturer’s protocol 
provided in Triglyceride Quantification Kit (Abcam- ab65336, Cambridge, MA) with plasma from 
male PANKO-C57 and WT mice at 2 months and 4-5 months of age obtained as described 
above. All samples were performed in triplicate. The assay was conducted at plasma dilutions of 
1:10 and 1:50 using water as a control to ensure values were within the standard curve given 
with the kit. The protocol pertaining to the colorimetric assay was utilized and samples were 
analyzed using a VersaMax Microplate Reader (Molecular Devices) with SoftMax® Pro software 
at a wavelength of 570 nm for optimal absorbance. All values and concentrations, presented in 
nM, were analyzed via GraphPad Prizm (Version 5) and statistical significance (p<0.05) between 
KO and WT was determined using 2-tailed Student t-test. 
 Glucose Tolerance & Insulin Tolerance Testing 
 For glucose-tolerance testing (GTTs), 4 month old male and female PANKO-C57 and WT 
mice were fasted overnight (>16 hrs) and injected intraperitoneally with 2 grams of glucose 
(Fisher Scientific) per kilogram of mouse body weight. Blood glucose levels were obtained as 
described above at 0, 15, 30, 60, and 120 minutes post glucose injection [60]. For insulin-
tolerance testing (ITTs), 4 month old male and female PANKO-C57 and WT mice were fasted 
for 4 hours (approx. a week after GTT was completed) and injected intraperitoneally with 1.0 
units of insulin (NovoLog®, Novo Nordisk, Plainsboro, NJ) per kilogram of mouse body weight. 
Blood glucose levels were measured as described previously at 0, 15, 30, 60, 90, and 120 
minutes post-injection of insulin [60]. All numerical values were analyzed via GraphPad Prizm 
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using SEM and statistical significance (p<0.05) was determined at each time point between KO 
and WT using 2-tailed Student t-test. 
 
Confirmation of PANKO-C57 and WT Genotypes 
 Prior to experimentation, all pups born to PANKO-C57 or WT parents were genotyped 
using DNA extracted from tail snips and amplified using primers for the KO and WT alleles as 
described in Experimental Design & Methods. In all, 203 pups were born, and 219 mice 
including the parent generation were genotyped. Mice born to PANKO-C57 and WT parents 
were analyzed for the presence of both the WT allele using -338 Kpn Forward and -35 TA 
Reverse primers, and the KO allele using the -338 Kpn Forward and KONeoP2 Reverse primers 
as previously described [45, 60]. Amplification of the PANKO allele resulted in an approximately 
500 bp product in PANKO-C57 mice, while amplification of the WT allele was confirmed in 
C57BL/6 WT mice by the appearance of a band between 850 and 1000 bp using the respective 
primer sets (Figure 6A). Further, the absence of either the PANKO or WT gene was confirmed in 
WT and PANKO mice, respectively, through PCR amplification and subsequent gel 
electrophoresis to ensure only homozygous mice were being used in experimentation. Negative 
amplification of the PANKO gene in WT mice was confirmed by the absence of a DNA fragment 
at approximately 500 bp in gel electrophoresis, when compared to positive (WT mouse with 
PANKO primers) and negative (WT mouse with WT primers) controls (Figure 6B). The same 
negative amplification was observed when attempting to amplify the WT allele in PANKO-C57 
mice. The absence of DNA bands was observed in gel electrophoresis between 850 and 1000 
bp, further indication that the PANKO-C57 mice were not heterozygous, but rather homozygous 
for knockout of the PANDER gene (Figure 6C). It was also confirmed that none of the WT mice 
that were genotyped and used in experimentation contained the KO allele, either. 
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Figure 6: PCR-Amplified PANKO-C57 and WT Allele Confirmations. 1% agarose gel 
electrophoresis for genotype verification of PANKO-C57 and WT mice, using 1 Kb Plus DNA Ladder 
(Invitrogen) as standard in all figures, with 500 bp and 850 bp fragments labeled. (A) Lanes 1-8: 
depicting PANKO DNA fragment at around 500 bp, Lanes 9 & 10: showing WT fragment between 850 and 
1000 bp. (B) Lanes 1 & 2: positive and negative control of WT mice with KO primers and WT mice with 
WT primers, respectively, and Lanes 3-11 confirming the absence of the KO gene as in the positive 
control. (C) Lanes 1-6: negative amplification of the WT allele in 6 KO samples. Shown by the absence of 
a fragment between 850 and 1000 bp in lanes 1-6. 
 
PANKO-C57 Mice Exhibit Lower Fasting Glycemia Short and Long Term 
 Characterization of the PANKO-C57 began with analyzing fasting blood glucose levels 
after a short (4 hours) and long term (overnight, approx. 16 hours) fast to determine overall 
insulin sensitivity. As stated previously, siRNA knockdown PANDER mice presented with lower 
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blood glucose levels as well as PANKO mice on C57/129 background, but only on HFD after 24 
and 48 hour fasts, and neither of these were global knockouts on C57BL/6 backgrounds [51, 
52, 61, 62]. PANKO-C57 male mice at 4 months of age exhibited a significantly lower fasting 
glycemia compared to age and sex matched C57BL/6J WT mice after fasting for 4 hours where 
the average PANKO-C57 blood glucose was 169.3 mg/dl + 6.9 versus WT average blood 
glucose of 225.8 mg/dl + 30.5 (P < 0.05) (Figure 7A). This same trend, with an increased 
significance, was also observed after a long-term fast of the same age and sex matched 
PANKO-C57 and WT mice, where PANKO-C57 mice presented with an average blood glucose of 
117.1 mg/dl + 5.9 versus WT average of 156.2 mg/dl + 12.2 (Figure 7B). 
    
Figure 7: Male PANKO-C57 Mice have Lower Fasting Glycemia Short and Long Term. (A): 
Blood glucose measurements (mg/dl) obtained from a tail vein poke after a short term fast for 4 hours 
and measured using standard glucometer, n= 8-11, P < 0.05. (B): Blood glucose measurements (mg/dl) 
measured after an overnight (long-term) fast from tail vein poke as previously decribed, n= 12-15, P < 
0.01. 
  
 The same procedure to measure fasting glycemia was performed with female PANKO-
C57 and WT mice that were 4 months of age. After a short-term fast, blood glucose 
concentrations of PANKO-C57 and WT females were very similar, where the average PANKO-
C57 concentration was 169.7 mg/dl ± 30.38 versus WT blood glucose concentrations of 181.1 
mg/dl ± 39.10 (n.s.) (Figure 8A). Greater differences were observed in female blood glucose 
concentrations after a long-term overnight fast, though differences were not significant. 
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PANKO-C57 females blood glucose average concentrations were 139.4 mg/dl ± 20.90 versus 
189.8 mg/dl ± 30.88 female WT average blood glucose concentration (n.s.) (Figure 8B). 
      
Figure 8: Female PANKO-C57 Display Lower Average Fasting Glycemia Trend After Short and 
Long Term Fast. (A) Blood glucose concentrations were measured (mg/dl) from PANKO-C57 and WT 
female mice after 4 hour fast through a tail vein poke and measured using a glucometer (n= 6-10). (B) 
Following a long-term overnight fast, female PANKO-C57 and WT mice blood glucose concentrations were 
measured via tail vein (n= 7-12). 
 
PANKO-C57 Mice Display Increased Body Weights Longitudinally 
 In order to characterize any effect that PANDER has in-vivo in terms of weight and 
weight gain, body weights of both male and female PANKO-C57 and WT mice were measured 
as described above in Experimental Design & Methods. PANTG pancreatic overexpressors 
displayed an increase in overall weight gain, whereas PANKO C57/129 mice were shown to 
have similar weights to WT when fed HFD. This lead us to determine if the knockout of PANDER 
in C57BL/6 mice would induce a difference in murine body weights that was not previously 
noted in any previous PANDER knockdown/knockout model [61, 82]. Beginning at 8 weeks of 
age, male PANKO-C57 mice displayed a significant increase in body weight at an average of 
25.16 g ± 0.35 compared to male WT mice averaging 23.32 g ± 0.3 (P < 0.001). This trend 
continued every 2-3 weeks weight was measured up to 23 weeks of age where PANKO-C57 
mice averaged 37.20 g ± 1.05 versus WT mice averaging 30.59 g ± 0.45 (P < 0.001) (Figure 
9A).  
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 Longitudinal body weight measurements were also performed every 2-3 weeks for 
female PANKO-C57 and WT mice to determine any significant differences as there were in the 
male mice. It was found that at 8 weeks of age, female PANKO-C57 mice were also significantly 
heavier than WT mice, where the average PANKO-C57 weight was 20.18 g ± 0.5 versus an 
average weight of 18.20 g ± 0.26 for WT mice (P < 0.001). The trend, though diminishing in its 
significance, also continued through to 21 weeks of age in the females where PANKO-C57 
females weighed an average of 25.84 g ± 1.17 compared to WT average weight of 23.01 g ± 
0.52 (P < 0.05) (Figure 9B). 
  
 
Figure 9: PANKO-C57 Mice Body Weight Measurements Trend Heavier than WT Mice. (A) Male 
longitudinal weights of PANKO-C57 and WT mice (in grams) obtained every 2-3 weeks from 8-23 weeks 
of age using a Beckman digital scale each time weights were obtained (n= 10-27). (B) Comparison of 
female PANKO-C57 and WT mice obtained beginning at 8 weeks of age through to 21 weeks of age, 
weighing every 2-3 weeks as described in Experimental Design & Methods (n= 9-22).  
 
Differential Expression of Metabolic Hormonal Analytes in PANKO-C57 
 To elucidate the mechanism of the significant observed decreased fasting glycemia in 
the male PANKO-C57 mice, a MAGPIX® Luminex (Austin, TX) Multiplexing approach was 
employed to determine concentrations of the fasting concentrations of the hormones insulin, 
glucagon, leptin, c-peptide, amylin, and resistin as described in Experimental Design & Methods. 
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While the previous PANKO C57/129 mice displayed an increase serum insulin concentration only 
measured during metabolic testing with no differences in leptin, c-peptide, glucagon or amylin 
and an ad-PANDER overexpressor model showed no difference in glucagon levels, neither 
contributed to an explanation for overall fasting glycemia, perhaps due to their genetic 
backgrounds [52, 54, 60].  
 To begin, overnight fasting plasma obtained from male PANKO-C57 and WT mice at 2 
months of age revealed significantly decreased insulin content in PANKO-C57 plasma compared 
to WT at 105.4 pg/mL + 36.4 versus 487.8 pg/mL + 34.6 (P < 0.001), respectively, with the 
same trend at 5 months of age, though not significant (Figure 10). Plasma glucagon levels were 
similar in PANKO-C57 and WT mice at both 2 and 5 months of age, where levels in WT at 2 
months and PANKO-C57 and WT at 5 months of age were below the minimal detectable content 
for the assay and therefore could not be quantified (Figure 10). Leptin, an adipose tissue-
derived hormone known to be elevated in the plasma with increasing fat mass and obesity, was 
significantly elevated in the plasma of PANKO-C57 mouse at both 2 and 5 months of age 
(Figure 10) [93, 94]. At 2 months old, PANKO-C57 mice plasma leptin levels were 779.7 pg/mL 
+ 76.6 versus WT plasma leptin levels of 253.3 pg/mL + 84.8 (P < 0.01), and though 
significance was lost at 5 months of age, plasma leptin concentrations in PANKO-C57 mice 
remained nearly 5 times higher than levels in WT mice. Lastly, c-peptide, the connecting 
peptide between insulin’s A and B chain in the proinsulin molecule used as a diagnostic tool for 
the measure of insulin in diabetes, was significantly decreased in PANKO-C57 at 2 months of 
age compared to WT mice, 386.0 pg/mL + 104.9 vs. 830.8 pg/mL + 46.98, respectively (P < 
0.01), coinciding with the decreased insulin levels at 2 months (Figure 10) [95]. Interestingly, 
when plasma c-peptide levels were evaluated at 5 months of age, PANKO-C57 mice displayed a 
significant increase in c-peptide concentration at 686.5 pg/mL ± 100.8 compared to WT c-
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peptide levels of 388.0 pg/mL ± 40.84 (P < 0.05) where they displayed a decrease in insulin 
levels from 2 to 5 months. Amylin and resistin, the last 2 hormones analyzed, were not able to 
be quantified due to the constraints of the assay in terms of quality controls and concentrations 
of both analytes fell below the minimal detectable range on the standard curve. 
 
Figure 10: Longitudinal Serum Hormonal Analyte Concentrations in PANKO-C57 and WT 
Mice. 2 and 5 month longitudinal Luminex multiplexing analysis of insulin, glucagon, leptin, and c-
peptide in PANKO-C57 and WT plasma fasted overnight, concentrations shown in pg/mL (n= 4-6). Not 
included: amylin and resistin, as concentrations were too low to quantify. 
 
Similar Corticosterone and Plasma Triglyceride Concentrations in PANKO-C57 
 Corticosterones, the murine version of glucocorticoids, were previously shown to be the 
primary cause of fasting hyperglycemia in ad-PANDER overexpressing mice compared to WT 
mice [52, 54]. Further, Li et al. reported that in their ad-PANDER hepatic overexpressor, there 
was an increase in serum triglycerides [51]. To further determine if plasma corticosterone levels 
contributed to the lower fasting glycemia in the PANKO-C57 and if increased serum triglycerides 
potentially contributed to the increased body weight with the plasma levels of leptin, assays 
were conducted to measure each in PANKO-C57 and WT fasting plasma. Corticosterone levels 
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were almost identical between PANKO-C57 and WT mice at both 2 and 5 months of age, where 
fasting corticosterone averages were lower at 5 months than at 2 months of age (Figure 11A). 
At 2 months, PANKO-C57 fasting corticosterone concentrations averaged 54.74 ng/mL ± 1.65 
versus WT averages of 57.00 ng/mL ± 10.31 (n.s.). These averages decreased in each cohort 
to 40.48 ng/mL ± 11.75 in PANKO-C57 mice versus 41.11 ng/mL ± 17.96 in WT mice at 5 
months of age (n.s.).  
 When examining plasma triglyceride content, at 2 months of age, PANKO-C57 mice 
presented with significantly higher plasma triglycerides at an average of 164.9 nM ± 7.939 
compared to WT mice at 140.7 nM ± 7.716 (P < 0.05) (Figure 11B). There was a switch in 
trend of longitudinal plasma triglyceride content at 5 months of age in the same PANKO-C57 
and WT mice, where PANKO-C57 mice displayed a lower plasma triglyceride concentration than 
WT mice, 147.2 nM ± 11.93 versus 158.7 nM ± 10.97 (n.s.), respectively. Interestingly, not 
only did PANKO-C57 plasma triglyceride content decrease longitudinally, but WT plasma 
triglyceride content increased longitudinally from 2 to 5 months of age (Figure 11B). 
   
Figure 11: Plasma Corticosterone and Triglyceride Levels in PANKO-C57 and WT Mice. (A) 
Overnight fasting plasma obtained from both PANKO-C57 and WT mice longitudinally at 2 and 5 months 
of age were analyzed for corticosterone content using Corticosterone ELISA Kit (ADI-900-097) 
(Farmingdale, NY), shown in ng/mL (n= 4). (B) Plasma triglyceride content from overnight fasting 
PANKO-C57 and WT mice was analyzed using Triglyceride Quantification Kit (Abcam- ab65336, 
Cambridge, MA), presented in nM (n= 5).  
 
0
20
40
60
80
2 Months 5 Months
WT
KO
A.
C
o
rt
ic
o
s
te
ro
n
e
 (
n
g
/
m
L
)
0
50
100
150
200
*
2 Months 5 Months
WT
KO
B.
P
la
s
m
a
 T
ri
g
ly
c
e
ri
d
e
 (
n
M
)
42 
 
PANKO-C57 Mice Display Enhanced Glucose Tolerance in Metabolic Tests 
 GTTs previously performed on male PANKO mice on C57/129 background revealed 
significant glucose intolerance as evidenced by increased blood glucose levels during GTT [60]. 
This glucose intolerance was accompanied by increased insulin levels at every time point during 
the GTT, both the result of impaired Ca2+ handling in pancreatic islets and impaired insulin 
clearance, respectively [60]. To explore whether these same traits were also apparent in 
PANKO-C57 mice, both male and female PANKO-C57 and WT mice underwent GTTs at 4 
months of age. Male PANKO-C57 mice displayed lower blood glucose levels at every time point 
during the GTT, 3 of which were significantly lower- 15 minutes, where PANKO-C57 blood 
glucose levels were 415.9 mg/dL + 45.9 versus WT blood glucose levels of 561.1 mg/dL + 33.2 
(P < 0.05), 60 minutes, where PANKO-C57 mice had blood glucose levels of 397.7 mg/dL + 
46.3 versus WT blood glucose levels 592.8 mg/dL + 8.3 (P < 0.01), and at the final time point 
in the GTT at 120 minutes where PANKO-C57 mice presented with blood glucose readings of 
290.1 mg/dL + 48.2 versus WT blood glucose levels of 472.3 mg/dL + 37.1 (P < 0.05) (Figure 
12A). This trend was confirmed by area under the curve (AUC) determination, where the 
PANKO-C57 AUC was significantly lower than WT (P < 0.01), a further indication that male 
PANKO-C57 mice are more glucose tolerant than male WT mice (Figure 12B).  
 This trend of enhanced glucose tolerance was also observed to a milder extent in 
PANKO-C57 females where, at the first 4 time points during the GTT, female PANKO-C57 blood 
glucose levels were decreased, and significantly decreased at 30 minutes post i.p. glucose 
injection where female PANKO-C57 blood glucose concentration averaged 378.4 mg/dl + 72.79 
versus WT at 531.3 mg/dl + 33.88 (P < 0.05) (Figure 12C). This mild enhancement in glucose 
tolerance was also corroborated by a decrease in PANKO-C57 GTT AUC, though it was not 
significant (Figure 12D). 
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Figure 12: GTT of PANKO-C57 Male and Female Mice Reveals Enhanced Glucose Tolerance. 
(A) glucose tolerance test (GTT) of male PANKO-C57 and WT mice showing average blood glucose 
(mg/dl) at each time point (in minutes) post 2 g/kg intraperitoneal glucose injection (n= 8-13). (B) Area 
under the curve (AUC) of male GTT shown in A. (C) GTT of female PANKO-C57 and WT mice depicting 
blood glucose readings (mg/dl) using glucometer at 0, 15, 30, 60, and 120 minutes post intraperitoneal 
glucose injection at 2g/kg concentration (n= 7-12). (D) AUC of female GTT shown in C. 
 
PANKO-C57 Mice Reveal Similar Insulin Sensitivity in Insulin Tolerance Test (ITT) 
 In addition to GTTs done at 4 months of age to characterize overall glucose tolerance, 
the same PANKO-C57 and WT mice underwent ITTs to characterize their peripheral sensitivity 
in response to a bolus injection of insulin on the C57BL/6 background. The previous PANKO 
C57/129 mouse were shown to have no difference in peripheral insulin sensitivity shown by ITT 
when fed both HFD for 5 and 10 weeks and normal chow, though generally, blood glucose 
levels were slightly higher in the PANKO C57/129 at each time point [60, 61]. The same was 
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also true for Ad-PANDER overexpressing mice and the PANTG mouse, where blood glucose 
levels (shown as % of baseline) were similar to WT during a GTT [52, 81, 82]. Additionally, 
another hepatic Ad-PANDER overexpressing model showed via a minimal model analysis, where 
mice are anesthetized during experimentation, that PANDER ultimately contributed to an overall 
decrease in insulin sensitivity [51].  
 Like the PANKO C57/129 mice, PANKO-C57 males showed no significant difference in 
raw blood glucose concentrations from 0-60 minutes during the ITT, though their blood glucose 
levels were trending lower than WT. Interesting, at 90 and 120 minutes of the ITT, the trend 
switched and the PANKO-C57 blood glucose average was higher than that of the WT mice, 
though differences in blood glucose measurements were not significantly different (Figure 13A). 
The similarity in blood glucose levels during the ITT was confirmed by AUC analysis, where the 
AUC for PANKO-C57 and WT were virtually the same 24490 ± 2048 versus 25610 ± 3558, 
respectively (n.s.), though PANKO-C57 AUC was slightly lower (Figure 13B). When evaluating 
the % from baseline change in blood glucose concentrations during the ITT, where timepoint 0 
is considered 100%, or baseline, the similarity between PANKO-C57 and WT insulin sensitivity 
became more profound, as did the trend reversal at 90 minutes, where PANKO-C57 mice 
average blood glucose % from baseline, 121.8 % ± 13.76, was significantly higher than WT at 
73.38 % ± 15.01 (P < 0.05) (Figure 13C). % from baseline change in blood glucose in PANKO-
C57 mice remained elevated at 120 minutes compared to WT, as well, though the difference 
was not considered significant. The AUC of % from baseline change in blood glucose of PANKO-
C57 and WT mice was also not significantly different, though PANKO-C57 AUC was slightly 
elevated compared to WT (13320 ± 1205 versus 12080 ± 2192, respectively), potentially due 
to the trend reversal at 90 and 120 minutes (Figure 13D). 
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Figure 13: Male PANKO-C57 and WT Similarities of Blood Glucose in ITT. (A) Male PANKO-C57 
and WT raw blood glucose numbers (mg/dl) during ITT at 0, 30, 60, 90, and 120 minutes post 
intraperitoneal insulin (1U/kg) injection recorded using glucometer (n= 8-12). (B) AUC of male ITT raw 
blood glucose readings in Figure A. (C) Male PANKO-C57 and WT blood glucoses as % from baseline 
during ITT, where 0 minute reading was baseline, calculated from values at each timepoint in Figure A (P 
< 0.05) (n= 8-12). (D) AUC of % from baseline blood glucose values during ITT for males shown in 
Figure C.  
 
 Though female mice previously showed no gross differences in metabolic analysis 
regarding PANDER in-vivo, differences in insulin sensitivity via ITTs have not been reported in 
C57BL/6 PANDER knockout mice [60]. Overall, when evaluating insulin sensitivity in female 
PANKO-C57 mice during an ITT and observing the raw blood glucose readings at each time 
point, there was no difference compared to female WT mice (Figure 14A). This was confirmed 
by differences in AUC of the ITT that were not significant, though PANKO-C57 average AUC was 
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slightly higher than WT (Figure 14B). Further, the same was true for female blood glucose 
concentrations during an ITT calculated as % change from baseline, where measurements at all 
time points were highly similar and correlated with the raw data (Figure 14C). The AUC for 
female blood glucose during an ITT as % change from baseline was also similar, despite the 
increase in WT AUC compared to PANKO-C57 (Figure 14D). 
  
    
Figure 14: ITT Measurement of Insulin Sensitivity in Female PANKO-C57 and WT Mice. (A) 
Raw blood glucose numbers (mg/dl) from female PANKO-C57 and WT after 4 hours of fasting during ITT 
at 0, 30, 60, 90, and 120 minutes post intraperitoneal insulin (1U/kg) injection recorded using glucometer 
(n= 7-11). (B) AUC of female ITT raw blood glucose readings in Figure A. (C) Female PANKO-C57 and 
WT blood glucoses as % from baseline during ITT, where 0 minute reading was baseline, calculated from 
values at each timepoint in Figure A (n= 7-11). (D) AUC of % from baseline blood glucose values during 
ITT for males shown in Figure C. 
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Summary of Initial PANKO-C57 Phenotypic & Metabolic Characterization 
 At the conclusion of the initial phenotyping experiments on the PANKO-C57 mice, 
several novel findings were observed when taking into consideration previous in-vivo PANDER 
studies. First, PANKO-C57 male mice have a significantly lower overall fasting glycemia 
compared to WT mice after fasting for both 4 hours and overnight. This is in contrast to the 
female PANKO-C57 fasting glycemias, which, though had a decreased trend, were not 
significantly lower. When the decrease in fasting glycemia was discovered at 4-5 months of age 
in the males, it was also accompanied by a decrease in overnight fasting insulin with a 
surprising increase in c-peptide, increased leptin, and no difference in glucagon or 
corticosterone levels compared to WT mice. When measured in plasma from the same PANKO-
C57 mice at 2 months of age in comparison to age and sex-matched WT mice, insulin was also 
decreased with the concordant decrease in c-peptide, leptin trended to be increased as well as 
glucagon, and corticosterone levels were also no different. Plasma triglyceride content was also 
significantly increased at 2 months old in the PANKO-C57 compared to 5 months old, where 
plasma triglycerides trended decreased. 
 The male specificity of PANDER’s role in-vivo, as first evidenced by the measurement of 
fasting glycemias, was also corroborated with enhanced glucose tolerance shown by GTTs and 
significantly increased weight of male PANKO-C57s compared to WT. Though PANKO-C57 
females also displayed significantly increased weights from 8-21 weeks of age, the trend of 
enhanced glucose tolerance shown by GTT was not as pronounced. Peripheral insulin 
sensitivity, however, was unaffected by the knockout of PANDER in both males and females as 
ITTs showed similar blood glucose levels and % change from baseline in response to a bolus 
injection of insulin. 
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 This initial phenotype, being male-dominant, suggests that the knockout of PANDER not 
only decreases fasting glycemia and increases glucose tolerance through hormonal analytes 
such as insulin, but it also facilitates a significant increase in weight, possibly through significant 
increases in plasma leptin and triglyceride concentrations.   
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CHAPTER THREE: HEPATIC INSULIN SIGNALING IN PANDER KNOCKOUT C57BL/6 
MOUSE 
 
Rationale 
 In-vitro, PANDER has been shown to bind to the liver membrane in HepG2 cells and 
inhibit insulin signaling at the liver by preventing the phosphorylation of both the Insulin 
Receptor (IR) and Insulin Receptor Substrate-1 (IRS-1) under insulin-stimulated conditions [39, 
62, 72]. Further down the insulin signaling cascade, PANDER was also shown to inhibit the 
insulin-stimulated activation of PI3K and phosphorylation of Akt, both critical insulin signaling 
molecules, in a dose- and time-dependent manner [39, 62, 72]. These results were exacerbated 
in in-vivo animal models of PANDER where different ad-PANDER overexpressors presented with 
an increase in lipogenic (SREBP-1, FAS, PPARγ) and gluconeogenic enzyme expression (G6Pase 
and PEPCK), and a decrease in phosphorylated Akt, AMPK, and FOXO1 protein expression [51, 
54]. The first PANTG overexpressing mouse also displayed a decrease in phosphorylated hepatic 
AMPK and ACC as well [82]. The initial phenotypes of various PANDER overexpressors has been 
shown to both support and contradict the phenotype of the initial PANDER knockout models. 
Concordant with the characterized overexpressing or transgenic models, PANDER knockout 
mice on mixed genetic background or siRNA models present with a lower HGP with higher % 
HGP suppression, lower expression of gluconeogenic enzymes and enhanced hepatic insulin 
signaling (in siRNA knockdown models), but with glucose intolerance and hyperinsulinemia [51, 
52, 54, 60]. The observed glucose intolerance in the previous PANDER knockout was attributed 
to impaired insulin secretion and hepatic insulin clearance. However, these studies lack a 
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concrete mechanism of action of hepatic signaling in a genetically pure model, like our PANKO-
C57 model. In addition, the mixed genetic background PANDER knockout mouse was never 
thoroughly investigated in the context of altered hepatic signaling despite the presence of 
increased HGP suppression. 
 Using the genetically pure PANDER knockout mouse on a C57BL/6 background (PANKO-
C57), the effect PANDER is having on the mechanism of hepatic insulin signaling, hepatic 
gluconeogenic enzyme expression, and glycogen content under fed and fasting conditions was 
ultimately determined. We hypothesized that the PANKO-C57 mice would have enhanced 
hepatic insulin signaling as demonstrated by increased phosphorylation of critical signaling 
molecules such as p-PI3K, Akt, and AMPK, along with increased downstream effector pathways 
such as in regard to increased glycogen synthesis and lipogenesis.  
 
Experimental Design & Methods 
 SDS-PAGE Western Blotting of Fasting and Fed Liver Protein 
 The liver tissue was obtained from male PANKO-C57 and WT mice at 5 months of age in 
the fasting (>16 hrs, overnight) or fed (insulin-stimulated) state. For fasting samples, mice 
were fasted overnight by removing all food and livers were extracted the next day after humane 
euthanization in accordance with experimental IACUC compliance (Appendix C). Livers were 
placed in CryoTube Vials (Thermo Scientific) and were subsequently flash frozen in liquid 
nitrogen and stored at -80°C until use. For insulin-stimulated livers, mice were fasted for 4 
hours and injected with 2 units/kilogram of insulin (NovoLog) before humane euthanization and 
flash freezing of whole livers. Serum was also collected 15-minutes post-injection of insulin in 
insulin-stimulated mice and just prior to euthanization in fasted mice. The SDS-PAGE gels were 
prepared using 100 mg of liver tissue homogenized using a TissueRuptor (Qiagen) in a 
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TPER/HALT Protease and Phosphatase inhibitor cocktail (Thermo Scientific). The supernatant of 
the liver lysate was quantified using a Pierce BCA Protein Assay (Thermo Scientific) following 
manufacturer’s protocol and analyzed using a VersaMax Microplate Reader (Molecular Devices). 
20-50 μg of the liver lysate was then loaded into a 10% tris/glycine Mini-PROTEAN® TGX™ 
Precast Gel (BioRad) SDS-PAGE with Precision Plus Protein™ WesternC™ Ladder (BioRad) to 
determine protein size. Transferring of the gel to a PVDF membrane was then performed using 
iBlot® semi-dry transfer technology per the manufacturer’s protocol provided (Invitrogen). The 
membrane was then blocked overnight at 4° (or for 2 hours at room temperature), rocking 
constantly, using StartingBlock Blocking Buffer (Thermo Scientific) and was probed for the 
presence of IRS-1, p-IRS-1, p-PI3K, SREBP-1 (all 4 from SantaCruz Biotechnologies), Akt, p-Akt, 
AMPKα, p-AMPKα, Acetyl CoA (ACC), p-Acetyl CoA (p-ACC), CREB, p-CREB, p-FOXO1, Glycogen 
Synthase, p-Glycogen Synthase, and GAPDH as a loading control (all 12 from Cell Signaling 
Technology) (Appendix A) at a 1:1,000 dilution in 10 mLs of StartingBlock Blocking Buffer 
overnight at 4°C. Blots were then washed and respective secondary antibodies, whether anti-
rabbit (BioRad), anti-mouse (BioRad) or rabbit-anti-goat (Santa Cruz) were added at a 1:3,000-
1:5,000 dilution in 10 mLs of StartingBlock Blocking Buffer with 1 μl of Precision Protein 
StrepTactin-HRP conjugate (BioRad) for illumination of the protein ladder for 1 hr at RT. Blots 
were then washed and developed using Pierce ECL Western Blotting Substrate (Thermo 
Scientific) and imaged using a Fuji LAS4000 imager (FujiFilm GE Healthcare). Once imaged, the 
blots were then stripped using Restore Western Blot Stripping Buffer (Thermo Scientific), 
shaking, at 37°C, blocked for > 2 hours at room temperature, rocking, and re-probed using 
another antibody. ImageJ was used in densitometric analysis of western blot images and all 
values and concentrations were analyzed via GraphPad Prizm (Version 5) and statistical 
significance (p<0.05) between KO and WT was determined using 2-tailed Student t-test. 
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 Measurement of Hepatic Triglyceride Content 
 To measure hepatic triglyceride content in PANKO-C57 and WT livers, fasting and 
insulin-stimulated liver samples were obtained from PANKO-C57 and WT mice as described 
above for SDS-PAGE western blotting. 100 mg of liver tissue was homogenized in 1 mL of 5% 
Triton X-100 and heated at 99°C for 5 minutes before being cooled to room temperature, then 
heated again for solubilization of all triglycerides and centrifuged for 2 minutes at top speed. 
Samples were then diluted 10-fold and used in the Triglyceride Quantification Kit (Abcam- 
ab65336) following manufacturer’s protocol in triplicate for each sample and at dilutions of 1:10 
and 1:100. The colorimetric assay was utilized and samples were analyzed using a VersaMax 
Microplate Reader (Molecular Devices) with SoftMax® Pro software at a wavelength of 570 nm 
for optimal absorbance, as it was for serum triglyceride measurement described previously. All 
values and concentrations, presented in nM, were analyzed via GraphPad Prizm (Version 5) and 
statistical significance (p<0.05) between KO and WT was determined using 2-tailed Student t-
test. 
 Evaluation of Hepatic Glycogen Content 
 To measure the differences in hepatic glycogen content between PANKO-C57 and WT 
mice, 10 mg of previously collected liver tissue from overnight fasted and insulin-stimulated 
mice was used. The 10 mg of liver tissue was homogenized in 200 μl of deionized water. The 
liver homogenate was then boiled, centrifuged, and the supernatant was collected and frozen at 
-80°C until use in accordance with the manufacturer protocol provided in the Glycogen Assay 
Kit (Abcam- ab65620). The assay was completed according to manufacturer’s protocol for the 
colorimetric assay and samples were read at 570 nm using VersaMax Microplate Reader 
(Molecular Devices). The assay was performed in triplicate for every sample using water as a 
control, and each sample was analyzed not only quantitatively but qualitatively observing color 
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change for samples that appeared off the standard curve. Each sample was also analyzed in 
dilutions of 1:10 and 1:100 as to ensure that one of the two data sets coincide with the 
standard curve (0.0004 mg/mL – 2 mg/mL). All values and concentrations (presented in μg/μl 
or in fold change) were analyzed via GraphPad Prizm and statistical significance (p<0.05) 
between KO and WT was determined using 2-tailed Student t-test. 
 Measurement of PEPCK and G6Pase Expression via RT-PCR 
 To examine the expression of gluconeogenic enzymes within the livers of the PANKO-
C57 and WT mice, livers were harvested and flash frozen from fasting and insulin-stimulated 
mice as described in SDS-PAGE Western Blotting methods. In order to prepare the lysate for 
RNA extraction, approximately 20 mg of liver tissue was homogenized in a mixture of Buffer 
RLT (Qiagen) & BME in a 1:100 dilution BME:RLT Buffer using a TissueRuptor (Qiagen). The 
supernatant, as a result of centrifuging, was then transferred to a gDNA eliminator column 
provided in the RNeasy Plus Mini Kit (Qiagen) to rid the sample of any remaining genomic DNA 
contaminants. Then, after a series of washes using ethanol and buffers provided with the kit 
according to the manufacturer’s protocol, the RNA was eluted using RNase-free water (Thermo 
Scientific). The RNA was then quantified along with determination of their purity using a 
NanoDrop (Thermo Scientific), and then subsequently frozen in the -80°C freezer until use. For 
real-time RT-PCR analysis, primer/probes for G6Pase, PEPCK, and 18s rRNA internal control 
(Applied Biosystems, Life Technologies, Grand Islands, NY) were used with the TaqMan Reverse 
Transcriptase systems (Applied Biosystems) and StepOne Plus ™ Systems (Life Technologies) 
for mRNA detection. All samples were run in triplicate with deionized water serving as a 
negative control to ensure there is no false amplification. Expression results were normalized to 
the 18s rRNA expression and relative levels were determined using the 2-ΔΔCt method [9]. All 
values were analyzed via GraphPad Prizm (Version 5) and statistical significance (p<0.05) 
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between KO and WT was determined using 2-tailed Student t-test, presented as fold change 
from WT. 
 Measurement of Plasma High-Density Lipoprotein (HDL) and Low-Density 
 Lipoprotein (LDL) Cholesterol 
 Plasma was obtained from 2 month old fasting PANKO-C57 and WT mice as previously 
described in Measurement of Hormonal Analytes and used in HDL and LDL/VLDL Cholesterol 
Assay Kit (Abcam- kit ab65390) according to manufacturer’s protocol. HDL and LDL were 
separated in the beginning of the assay and analyzed separately to ensure accurate 
concentration determination of each. Each sample was run in triplicate with a water control and 
concentration was analyzed using a VersaMax Microplate Reader (Molecular Devices) at 570 
nm. All values and concentrations (presented in μg/μl) were analyzed via GraphPad Prizm and 
statistical significance (p<0.05) between KO and WT was determined using 2-tailed Student t-
test. 
 
Fasting PANKO-C57 Mice Exhibit Enhanced Hepatic Insulin Signaling  
 Previous data regarding PANDER murine models and insulin signaling have thus far been 
convoluted and inconclusive due to overall differences in models where signaling was 
characterized. 2 different ad-PANDER overexpressing models suggested that PANDER disrupts 
the activation of FOXO1, AMPK, and Akt, in addition to enhancing signaling through CREB to 
induce fasting hyperglycemia [51, 54, 62]. Additionally, these accounts were further 
corroborated by the PANTG where levels of phosphorylated AMPK and ACC were decreased due 
to PANDER overexpression [96]. However, the complete elucidation of PANDER’s effects on the 
entire insulin signaling cascade has never been fully evaluated in any in-vivo model until this 
PANKO-C57 characterization.  
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Figure 15: Overnight Fasting Hepatic Signaling in PANKO-C57 and WT Mice. Figure depiction of 
10% SDS-PAGE gels loaded with 20-50 μg of liver lysate protein from overnight fasted PANKO-C57 and 
WT mice outlined in Experimental Design & Methods above. All primary antibody dilutions presented were 
1:1000 with goat-anti-rabbit (BioRad) secondary antibody dilutions of 1:3000-1:5000. Images presented 
are representative of multiple replicate western blots that were analyzed (n= 3). 
 
 After fasting overnight, PANKO-C57 mice display an overall decrease in protein 
expression levels of IRS-1 (Figure 15). However, beginning at phosphorylated-PI3K and 
continuing down through p-Akt, p-ACC, p-AMPK, p-GS and mature SREBP-1c, all protein 
expressions are increased, indicating an enhancement of phosphorylation activity in the insulin 
signaling cascade (Figure 15). All of these increases in protein phosphorylation between 
PANKO-C57 and WT mice are relative to total levels of each respective target protein and 
normalized to GAPDH levels serving as loading control for each individual mouse. Additionally, 
levels of SREBP-1c precursor, the transcription factor attached to the endoplasmic reticulum 
(ER) and nuclear envelope released in times of sterol-depletion to generate the mature SREBP-
1, were similar between PANKO-C57 and WT mice (Figure 15) [103]. Glycogen Synthase (GS) 
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levels appeared similar between both groups, but when comparing phosphorylated-GS levels, 
PANKO-C57 mice displayed an overall increase in protein expression, indicating that in the 
fasting state in these mice, the GS protein is inactivated and glycogenolysis is occurring. The 
increase in phosphorylation of these insulin signaling proteins, including GS, indicates an 
enhancement in overall insulin signaling in PANKO-C57 mice in the fasting state. Unfortunately, 
due to technical limitations with regard to lack of successful detection of target protein by 
western analysis, phosphorylated IRS-1, total CREB, phosphorylated CREB, and phosphorylated 
FOXO1 protein levels were unable to be properly measured despite utilizing commercially 
available antibodies that were generated for detection of target proteins and previous reports 
were unable to be corroborated in PANKO-C57 and WT C57BL/6 mice.  
 
Insulin-Stimulation Enhances Hepatic Insulin Signaling in PANKO-C57 
 Expression of insulin signaling proteins in response to insulin stimulation in the PANTG 
murine model revealed an overall decrease in expression levels of both phosphorylated AMPK 
and ACC, as it did in the fasted state, compared to total levels of the same proteins [96]. Apart 
from in-vivo models, HepG2 cells infected with ad-PANDER for only 48 hours displayed a 
significant decrease in levels of phosphorylated Akt and FOXO1 after various lengths of times of 
insulin treatment, further demonstrating PANDER’s negative regulatory effects on insulin 
signaling on the liver in-vitro [51]. However, any further characterization of affected protein 
levels of insulin signaling proteins post-insulin stimulation has remained to be characterized 
compared to fasting levels in the same murine models, especially in the PANKO-C57 pure 
PANDER knockout model.  
 15 minutes after insulin stimulation in PANKO-C57 mice, expression of IRS-1 appears to 
be slightly decreased compared to WT mice (Figure 16). 
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Figure 16: Insulin-Stimulated Effect on Hepatic Signaling Protein Expression in PANKO-C57. 
Protein expression measured as outlined in Experimental Design & Methods using 20-50 μg of liver 
protein lysate from PANKO-C57 and WT mice injected with insulin. PVDF membranes with transferred 
proteins were incubated with primary antibodies at 1:1000 dilution and goat-anti-rabbit secondary 
antibody (BioRad) at 1:3000-1:5000 dilution in StartBlock (Thermo Scientific). 
 
However, insulin-stimulated levels of p-PI3K were highly upregulated in the PANKO-C57 with an 
unexpected minimal decrease in p-Akt levels compared to WT mice, though protein expression 
levels are different in each mouse compared to total Akt levels (Figure 16). Both mature SREBP-
1c and SREBP-1c precursor expression levels were increased in the PANKO-C57 when 
stimulated with insulin in striking difference to fasting levels, where there was no difference in 
SREBP-1c precursor expression between the PANKO-C57 and WT mice. Further, insulin-
stimulated p-AMPK and p-ACC expression levels appeared to be similar in both PANKO-C57 and 
WT mice (Figure 16). Lastly, expression of phosphorylated GS was lesser in PANKO-C57 mice 
compared to WT mice where there appeared to be no significant differences, if any, in non-
phosphorylated GS levels in both cohorts of mice. All protein expression intensities were 
compared to their respective total protein levels for each mouse when examining 
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phosphorylated protein expression and all proteins were normalized to GAPDH protein loading 
control (Figure 16). 
 
Decreased Fasting Hepatic Triglyceride Content in PANKO-C57 Mice  
 The PANTG overexpressing mouse was recently shown to display an increase in hepatic 
triglyceride concentration while fed a normal chow diet compared to WT mice, much like that of 
an Ad-PANDER overexpressing model that revealed significantly higher liver triglyceride content 
[51, 82]. Surprisingly, an additional Ad-PANDER murine model revealed decreased liver 
triglycerides while fasting, opposite of what was observed in the hepatic Ad-PANDER 
overxpressor [51, 54]. Further, the siRNA PANDER knockdown model revealed a reversal of 
hepatic steatosis in db/db mice, but hepatic triglyceride concentration has never been evaluated 
in a C57BL/6 PANDER knockout, or the previously characterized PANKO C57/129 model until 
now [51, 54].  
 Evaluation of hepatic triglyceride content in male PANKO-C57 mice revealed an 
approximate 4-fold increase in triglyceride concentration when stimulated with insulin, where 
concentrations were 6.149 nM ± 1.595 versus WT concentrations of 1.517 nM ± 0.7263, 
though values were not significant (Figure 17). After fasting overnight, interestingly, the 
PANKO-C57 male mice displayed a significant decrease in hepatic triglyceride content compared 
to WT mice, 7.021 nM ± 1.131 versus 10.87 nM ± 0.2170, respectively (P < 0.05) (Figure 17). 
Also interesting to note, hepatic triglyceride content of WT mice was significantly increased (P < 
0.01) in the fasting state compared to insulin-stimulated hepatic triglyceride concentrations. WT 
triglyceride concentration was approximately 6-fold higher in fasting compared to insulin-
stimulated conditions, whereas PANKO-C57 hepatic triglyceride content was similar in fasting 
and fed conditions. 
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Figure 17: PANKO-C57 Mice Hepatic Triglyceride Concentrations Fasted and Insulin-
Stimulated. Comparisons of PANKO-C57 and WT hepatic triglycerides using 100 mg of either overnight 
fasting or insulin-stimulated liver sample and measured via Triglyceride Quantification Kit (Abcam- 
ab65336). Concentrations presented in nM, P < 0.05 denoted by single asterisk (n = 3 for each group). 
 
PANKO-C57 Mice Exhibit Increased Fed Hepatic Glycogen Stores 
 To date, the only differences observed in glycogen stores in PANDER murine models has 
been in the PANTG model, where glycogen stores were significantly increased while being fed 
HFD [82]. No differences in glycogen stores were observed in the previous PANKO C57/129 
mouse, prompting the measurement of glycogen concentrations in the PANKO-C57 in both the 
fasting and insulin-stimulated conditions, as glycogen storage and glycogenolysis are central 
hepatic metabolic processes [54].  
 Insulin-stimulated hepatic glycogen concentrations were significantly increased in the 
PANKO-C57 mice where their glycogen concentrations were 142.7 μg/μl ± 17.16 versus WT 
glycogen concentration at 1.169 μg/μl ± 0.1085 (P < 0.01) which correlated to a 122.1 fold 
increase in glycogen stores over WT (P < 0.01) (Figure 18 A & B). After having been fasted 
overnight, glycogen stores were depleted in both PANKO-C57 and WT mice, where PANKO-C57 
mice had a lower concentration of hepatic glycogen at 1.737 μg/μl ± 0.4636 versus WT mice 
with fasting hepatic glycogen concentration at 3.226 μg/μl ± 0.4003 (n.s.) which resulted in an 
almost 2 fold increase in glycogen stores within WT mice (Figure 18 A & C).  
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Figure 18: Hepatic Glycogen Stores in PANKO-C57 and WT Mice. (A) Comparison of hepatic 
glycogen concentration between PANKO-C57 and WT mice, presented in μg/μl, in the insulin-stimulated 
(2U/kg of insulin) and overnight fasting conditions (n= 3). (B) Fold change between WT and PANKO-C57 
hepatic glycogen stores, presented in fold change above WT, in the insulin-stimulated state shown on the 
left in A. (C) Fold change in hepatic glycogen concentrations, given in fold change above/below WT, in 
the fasting state shown on the right in A. 
 
Gluconeogenic Enzyme Expression is Upregulated in Fed PANKO-C57 Mice 
 Gluconeogenesis is the main contributor to HGP after approximately 8-12 hours of 
fasting, and PANDER has been linked to upregulating expression of gluconeogenic enzymes, 
G6Pase and PEPCK, in ad-PANDER overexpressing mice after only 3-4 hours of fasting after a 
GTT, contributing to an overall increased fasting glycemia [2, 25, 54]. siRNA PANDER 
knockdown db/db mice and the C57/129 PANKO mouse displayed a decrease in both G6Pase 
and PEPCK, and this decrease was observed in the PANKO C57/129 mouse after an overnight 
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fast, surprisingly, with no reports of gluconeogenic enzyme expression while insulin-stimulated 
[51, 54].  
 Surprisingly, when evaluated under insulin-stimulated conditions, PANKO-C57 mice 
displayed not only a significant increase in G6Pase expression compared to WT (45.36 ± 10.71 
vs. 3.807 ± 1.160, P < 0.01), but an almost 8-fold higher relative gene expression of PEPCK 
(86.28 ± 49.8 vs. 11.08 ± 4.452, respectively), though not significant (Figure 19A). 
Interestingly, as opposed to the significant decrease in expression of G6Pase and PEPCK in the 
C57/129 PANKO mice observed after an overnight fast, the PANKO-C57 mice displayed no 
significant difference in expression of either G6Pase or PEPCK, though PEPCK expression was 
trending lower than that of WT (Figure 19B) [52]. Fasting relative expression levels of G6Pase 
in PANKO-C57 mice were similar to that of WT mice where relative gene expression was 3.117 
± 1.215 versus WT G6Pase expression levels of 2.956 ± 1.062 (n.s.). Further, fasting 
expression levels of PEPCK in PANKO-C57 averaged 3.756 ± 1.339 versus WT mice at 5.105 ± 
1.378 (n.s.).  
      
Figure 19: Fasting and Insulin-Stimulated Relative Gene Expression of G6Pase and PEPCK in 
PANKO-C57 Mice. (A) Using the 2-ΔΔCt method for determination of relative expression levels, insulin-
stimulated expression of G6Pase and PEPCK was measured in RNA isolated from 10 mg of liver tissue 
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from PANKO-C57 and WT mice (n= 4-6). (B) Overnight fasting relative expression of G6Pase and PEPCK 
measured in isolated hepatic RNA and calculated using 2-ΔΔCt relative gene expression calculation (n= 6). 
 
Higher HDL and Lower LDL Plasma Cholesterol in PANKO-C57 Mice 
 
 Overexpression of hepatic PANDER was previously shown to have little effect on 
HDL/LDL cholesterol concentrations specifically within the liver, though the same hepatic 
PANDER overexpressing mice interestingly displayed a significant increase in serum VLDL 
concentrations [51]. Hepatic PANDER siRNA knockdown in db/db mice also revealed 
significantly lower circulating VLDL in contrast to hepatic overexpressors [51]. The PANTG 
mouse, on the other hand, was reported to display an increase in plasma HDL cholesterol with 
similar LDL plasma cholesterol levels, perhaps suggesting a role for PANDER in maintaining 
circulating cholesterol biosynthesis, which we evaluated in fasting PANKO-C57 plasma obtained 
from mice at 2 months of age [82]. Like the PANTG, the PANKO-C57 presented with an increase 
in plasma HDL cholesterol with a concentration of 0.701 μg/μl versus WT plasma HDL 
concentration of 0.480 μg/μl (Figure 20). Plasma LDL cholesterol, on the other hand, and unlike 
that of the previous PANDER siRNA knockdown model, trended slightly lower in the PANKO-C57 
at a concentration of 0.075 μg/μl versus WT plasma LDL cholesterol concentration of 0.103 
μg/μl (Figure 20).  
 
Figure 20: Plasma HDL/LDL Cholesterol Concentrations in PANKO-C57 and WT Mice. 2 months 
HDL (left) and LDL (right) cholesterol measurement from fasting plasma of PANKO-C57 and WT mice 
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shown in concentration of μg/μl using HDL and LDL/VLDL Cholesterol Assay Kit (Abcam- kit ab65390) 
(n= 1).  
 
Summary of Hepatic Signaling Mechanisms in PANKO-C57 Mice 
 
 The complete elucidation of hepatic insulin signaling in PANKO-C57 mice provides not 
only clarity to earlier contradictory evidence, but also novel findings regarding PANDER’s role in 
effecting hepatic insulin signaling, particularly during the fasted state. The PANKO-C57 mice 
displayed an upregulation of all of the critical insulin signaling molecules in the insulin signaling 
pathway after an overnight fast, where 3 of the 5 protein expression differences were 
significant when analyzed using densitometry, denoted by asterisks and shaded dark green in a 
heat map (Table 1). This supports the idea that PANDER’s most severe effects are in the fasted 
state as opposed to in insulin-stimulated conditions. When stimulated with insulin, the PANKO-
C57 mice displayed selectively different trends in protein expression within the insulin signaling 
cascade as in the fasted state, though no values were significant or expression levels were not 
different compared to WT (Table 1).  
Table 1: Summary of Western Results Comparing Hepatic Signaling in PANKO-C57 versus WT 
as a Heat Map Representation 
 
* Western results are shown in a heat map with up arrows (shaded in green) or down arrows (shaded in 
red) denoting increased or decreased phosphorylation (normalized to total target protein and loading) or 
abundance (for IRS-1), respectively. * denotes statistical significance according to densitometry and are 
highlighted by a darker shade of red or green.  NC refers to no change measured and is shaded in yellow. 
 
Signaling 
Molecule 
Fasting Insulin 
Stimulated 
IRS-1  
p-PI3K   
p-Akt   * 
p-AMPK   * NC 
p-ACC  NC 
mSREBP-1   *  
p-GS     **  
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 Beyond insulin signaling, the PANKO-C57 mice presented with increased hepatic 
triglyceride content post-insulin stimulation but lower hepatic triglyceride content after an 
overnight fast compared to WT mice. Glycogen stores were also significantly increased along 
with hepatic triglycerides after insulin stimulation and were almost depleted after fasting 
overnight. Interestingly, as opposed to previous PANKO C57/129 and siRNA PANDER 
knockdown models, expression of gluconeogenic enzymes G6Pase and PEPCK were increased in 
the PANKO-C57 after insulin stimulation and were similar to WT after fasting, though PEPCK 
was evidenced to be slight decreased. Lastly, plasma levels of HDL cholesterol were higher with 
decreased levels of plasma LDL cholesterol in the PANKO-C57 mice at 2 months of age 
compared to age and sex matched C57BL/6 WT mice.  
 These novel findings discovered as a result of the elucidation of hepatic signaling both 
fasting and insulin stimulated (fed) along with glycogen, triglyceride, and cholesterol 
measurement in the PANKO-C57 indicate PANDER plays a significant role in affecting glycemic 
regulation, particularly in the fasting state. Furthermore, PANDER also potentially affects hepatic 
stores of glycogen and differentially affects gluconeogenic enzyme expression and HGP under 
conditions of insulin abundance.  
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CHAPTER FOUR: CONCLUSIONS 
 
PANKO-C57 Compared to Previous PANDER Knockout/Knockdown Models  
 After complete phenotypic and hepatic signaling characterization of the global PANDER 
knockout mouse on a C57BL/6 genetic background, the PANKO-C57 mouse, several similarities 
and differences were discovered between the PANKO-C57, the previous PANKO C57/129 mixed 
genetic PANDER knockout, and the acute ad-PANDER db/db siRNA PANDER knockdown mouse 
(Table 2). The PANKO-C57, devoid of any circulating PANDER, exhibited an enhanced glucose 
tolerance and decreased fasting glycemia, like that of the siRNA PANDER knockdown, but unlike 
that of the PANKO C57/129 [51, 54, 60]. Interestingly, in full contrast to the siRNA knockdown 
model, the PANKO-C57 presented with an overall increase in both plasma and hepatic 
triglycerides, neither of which were even evaluated in the PANKO C57/129, suggesting that 
PANDER may work through alternate mechanisms up or downregulate triglyceride synthesis 
under different conditions [51, 60]. The fact that none of the 3 PANDER knockout/down models 
display an enhanced peripheral insulin sensitivity indicates that PANDER’s effects are solely 
focused on the liver to upregulate glucose output, as evidenced by the decrease in 
gluconeogenic enzyme expression in both the PANKO C57/129 and the siRNA knockdown, but 
not in the PANKO-C57, indicating an additional mechanism for their decreased fasting glycemia 
[51, 54]. However, in light of the lack of decreased glconeogenic enzyme expression, the 
PANKO-C57 has, thus far, been the only model to exhibit a decrease in fasting glycemia, 
increase in hepatic glycogen stores, and enhanced hepatic signaling through critical insulin 
signaling molecules involving p-PI3K, p-Akt, and SREBP-1, among others, which was not fully 
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characterized in the siRNA knockdown model and not attempted in the PANKO C57/129 [51]. 
This suggests that the PANKO-C57, as opposed to comparable models, represents a more 
enhanced phenotype for identification of PANDER function. 
Table 2: Comparisons of PANDER Knockout C57/129 & db/db siRNA Knockdown Murine 
Models to PANKO-C57 
 
PANKO-C57 as an Improved PANDER Murine Model 
 Advantages 
 The PANKO-C57 mouse offered great advantages in terms of phenotypic 
characterization and offered clarity, in addition to further understanding, of PANDER’s role in-
vivo. First, this PANKO-C57 mouse was the first and only PANDER model to depict significant 
phenotypic differences between female PANKO-C57s and WT mice, including increases in body 
weights and enhanced glucose tolerances, in addition to trending decreased fasting glycemia. 
Though PANDER’s effects were ultimately determined to be male-dominant, as they are 
regarding other PANDER murine models, shown by significant decreases in fasting glycemia and 
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significant enhances in glucose tolerance in male PANKO-C57 mice, the differences observed 
here in female PANKO-C57s is novel [54, 60, 82, 96]. Additionally, given that these PANKO-
C57s are on a purebred C57BL/6 genetic background, any abnormalities due to the genetic 
background with heterozygosity and gene expression, which was the case with the PANKO 
C57/129 co-isogenic strain, are abolished, ensuring in excess of 99% homology within the 
breeding colony of the congenic PANKO-C57 strain [91, 92]. When compared to the mixed 
genetic PANKO C57/129, the pure bred PANKO-C57 was able to exhibit traits such as enhanced 
glucose tolerance, decreased fasting insulinemia, and differences in body weight and fasting 
glycemic levels not previously observed in the PANKO C57/129 [54, 60, 61]. These observed 
differences can only be attributed to the different genetic backgrounds, PANKO C57/129 versus 
PANKO-C57, and suggest that the PANKO-C57 is the optimal PANDER knockout model. Also, 
because the PANKO C57/129 mixed genetic mouse revealed defects in insulin secretion due to 
improper calcium handling, it is possible that those defects are also present in the PANKO-C57 
[60]. However, any of the possible effects of defective insulin secretion in the PANKO-C57 were 
completely masked by the significantly enhanced hepatic insulin sensitivity that was not 
observed in the PANKO C57/129.  
 Additionally, because the PANKO-C57 has integrated the null PANDER mutation into its 
genome for transmission to all generations, there are multiple advantages to the PANKO-C57 
over the acute siRNA PANDER knockdown db/db model. First, not only was siRNA knockdown 
performed in a mouse accepted as a suitable model for type 2 diabetes, but siRNA knockdown 
via tail vein injection was only performed 3 days prior to all experimentation [51, 53]. Because 
knockdown of a gene via siRNA is considered transient in the case of this PANDER model, not 
only is continuous application of the siRNA needed to elicit a long-term effect, but the efficiency 
of delivery and off-target effects of the siRNA need to be taken into consideration as well [51, 
68 
 
98]. The PANKO-C57 offers an advantage to this model in that the effects of the null PANDER 
mutation are able to be studied longitudinally in these mice throughout their lifespan, from 
weaning to euthanization. This allows us to observe not only the effects of globally knocking out 
PANDER in these purebred C57BL/6 mice, but also to observe how the aging process effects 
PANDER and perhaps the development of type 2 diabetes, considered an adult-onset disorder 
[12-15]. Several assays and screenings presented in this study were able to be performed at 2 
and 5 months in the same mice, whereas siRNA knockdown models were not due to the short-
term longevity of the siRNA effects [51, 98]. Further, the db/db mouse is known as a model of 
type 2 diabetes because of a point mutation in the leptin receptor that results in abnormal 
signal transduction along with gross obesity, leptin resistance, and type 2 diabetic hallmarks 
[53]. It is potentially for this reason that such a difference in fasting plasma leptin 
concentrations were observed in the PANKO-C57 that could not possibly be observed in the 
siRNA knockdown model being that the siRNA was performed on a db/db mouse.  
 Limitations 
 Though the PANKO-C57 is considered to be on an optimal background to observe the 
effects of and phenotype null mutations, there are limitations to this study [91, 92]. First, the 
lack of a tissue-specific PANKO-C57 is a potential drawback to completely characterizing 
PANDER’s implications in-vivo. To delineate the relative contribution of various tissue-derived 
PANDER from the liver, intestine, and pancreas, an argument could be made that tissue-specific 
knockouts pertaining to these PANDER producing tissues would further refine the synergistic 
role of this molecule. Thus far, the PANTG has been the only tissue-specific PANDER 
overexpressing murine model created apart from other transient/acute ad-PANDER models [81, 
82, 96]. The PANTG, a pancreas-specific PANDER overexpressor, has shed light on many 
inconsistencies presented in other PANDER overexpressing models, and the creation of either a 
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pancreas or liver-specific PANDER knockout would allow for improved clarity regarding 
PANDER’s effects on/in specific organs and tissues [81, 82, 96]. Additionally, the PANDER 
receptor has yet to be elucidated. Though the crystal structure of PANDER was discovered early 
this year, the lack of a definitive PANDER receptor greatly hinders not only characterizing 
PANDER’s interactions, but also potential novel therapeutics in preventing PANDER’s actions 
[40]. That’s not to say that the PANKO-C57 was lacking, in any way, valuable evidence that its 
phenotypic characterization adds to our knowledge regarding PANDER.  
 Further limitations regarding this study involve the n, or the number of mice, involved in 
each analysis. Though an n value of 3 is able to generate statistical significance, perhaps using 
more mice in each of the studies would reduce the standard error from the mean (SEM) values 
and allow for greater significance to be reached. Many of the PANKO-C57 studies presented 
including body weight measurements, GTTs, ITTs, and fasting glycemic measurements here 
involved up to 10-15 mice and sometimes greater, where the greatest differences to WT were 
observed, but technical limitations involving multiple assay optimizations hindered the ability to 
assess more mice. Further, PANKO C57/129 mice displayed decreased fasting glycemia with 
decreased insulinemia when stimulated with glucose and decreased fasting G6Pase and PEPCK 
when fed HFD for up to 10 weeks [61]. This insinuates that these PANKO C57/129 mice could 
be offered some protection to developing fasting hyperglycemia, a hallmark of type 2 diabetes 
and an effect of PANDER, by ingestion of a HFD [52, 61]. As a result of these findings in the 
mixed genetic PANKO C57/129, it is plausible to say that the effects of HFD feeding should be 
evaluated on PANKO-C57 mice also. The genomic deletion of PANDER in C57BL/6 mice could 
potentially offer an even higher degree of protection against hyperglycemia and 
hyperinsulinemia brought on by a HFD that was observed in the PANKO C57/129, given that the 
PANKO-C57s already display a decreased fasting glycemia and insulinemia. Unfortunately, due 
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to the time constraints regarding this project, the effects of HFD on PANKO-C57 glycemic 
regulation and glucose homeostasis was not able to be determined (although initiated), but 
should be considered in future directions regarding PANKO-C57 characterization.  
 Lastly, though hepatic insulin signaling was determined to be enhanced in the PANKO-
C57 in this study, inconsistencies remained regarding increased and similar gluconeogenic 
enzyme expression in insulin-stimulated and fasting conditions, respectively. Previously, the 
PANKO C57/129 and siRNA PANDER knockdown presented with decreased gluconeogenic 
enzyme expression which was corroborated in the PANKO-C57 only in the fasted state based on 
a non-statistical trend [51, 54]. To circumvent these inconsistencies and better understand HGP 
within the PANKO-C57, a hyperinsulinemic-euglycemic clamp study should be performed and 
this model may eventually be sent for clamp studies for this purpose. HEC studies are 
considered to be the gold standard and optimal method for determining hepatic insulin 
sensitivity, peripheral glucose utilization, insulin action, and HGP [97]. HECs were performed on 
both the PANTG and the PANKO C57/129 mice and revealed increased and decreased HGP, 
respectively, along with decreased and increased % HGP suppression, respectively, which 
greatly added to the overall phenotypes observed in each mouse [60, 81]. These HEC studies 
should optimally be utilized as a confirmatory measure for enhanced hepatic insulin sensitivity 
observed in the PANKO-C57 via multiple western blots, however, due to technical and monetary 
limitations, HEC studies were not able to be completed within the realm of this study. 
Nevertheless, the findings regarding PANDER and the characterization of the PANKO-C57 
murine model that were gained from this study, in light of the few limitations, are novel and 
further corroborate evidence that PANDER plays a major role in glycemic regulation, particularly 
at the hepatic level.  
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PANDER’s Role in Glycemic Regulation & Type 2 Diabetes Based on PANKO-C57 
 PANDER’s association with type 2 diabetes has been characterized thus far in terms of 
in-vitro data and findings primarily from acute ad-PANDER overexpressors and knockdown 
models. However, with the characterization of the PANKO-C57 presented in this study, clarity 
has been gained regarding PANDER’s actions in the fed, fasting, and type 2 diabetic states. 
 PANDER in the Fed State 
 In the fed state, based on previous PANDER data combined with novel findings from this 
PANKO-C57 phenotypic characterization, upon ingestion of a meal, blood glucose will rise by the 
release of broken down sugars and carbohydrates into the bloodstream, or glucose appearance 
[1, 4, 5]. The rising blood glucose stimulates pancreatic islets to secrete both PANDER and 
insulin from β-cells [66]. Given that exogenously produced PANDER does not affect insulin 
levels or secretion in-vivo and PANKO C57/129 mice islets reveal improper calcium handling 
resulting in decreased glucose stimulated insulin secretion, PANDER seems to further enhance 
insulin secretion from pancreatic islets [52, 54, 60]. Insulin, being the dominate molecule, and 
being further facilitated by PANDER, will bind to its respective IR on the hepatic membrane and 
enhances insulin signaling, lipogenesis, and enhance hepatic glycogen stores [51, 72]. 
Additionally, insulin enhances PANDER secretion from α-cells, further allowing PANDER to 
augment the effects of insulin and insulin sensitivity [52, 69]. All of these factors contribute to 
the maintenance of euglycemia after meal ingestion when all other contributions to blood 
glucose and glycemia are normal (Figure 21). 
 Interestingly, in the PANKO-C57, though there is no circulating PANDER to facilitate 
insulin secretion and action, the mice display enhanced hepatic insulin sensitivity in the insulin-
stimulated (fed) state and respond greater to insulin than C57BL/6 WT mice. This is shown 
through an upregulation of critical insulin signaling molecules including p-PI3K, p-Akt, and 
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SREBP-1, stimulating increased hepatic triglyceride content, and significantly higher glycogen 
stores. This could potentially be due to the fact that though PANDER assists insulin and 
promotes its secretion from β-cells, insulin plays a counterregulatory role to PANDER. When 
PANDER is no longer present, insulin’s effects are potent and unrivaled in-vivo, lending to the 
fact that fasting PANKO-C57 mice are particularly more insulin sensitive than WT mice. 
Additionally, when PANDER is knocked out on a pure C57BL/6 background and all other genetic 
inconsistencies are eliminated, insulin is able to work maximally to enhance glucose 
disappearance, observed in the PANKO-C57 mice where they exhibit enhanced glucose 
tolerance through lower blood glucose levels during a GTT. 
 
Figure 21: PANDER’s Predicted Actions in the Fed State Based on PANKO-C57 Model. 
Depiction of PANDER’s role in the fed states where (1) ingestion of a meal increases blood glucose levels, 
stimulating (2) pancreatic islets to secrete PANDER and insulin, where PANDER further allows for insulin 
secretion and action from the islets and insulin’s affects dominate that of PANDER’s at the hepatic level 
and allow for (3) enhanced insulin signaling, increased lipogenesis, and enhanced glycogen storage, 
leading to (4) the further maintenance of euglycemia and insulin sensitivity (adapted from Wilson et al. 
2011) [52]. 
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 PANDER in the Fasting State 
 When fasting, PANDER’s mechanism of action is slightly less understood, but it has 
appeared as though PANDER exerts a greater negative role on glycemia under fasting 
conditions. Decreasing blood glucose levels stimulate the release of glucagon from α-cells in 
pancreatic islets [1]. With regard to PANDER secretion from pancreatic α-cells, L-arginine, a 
stimulator of glucagon, highly upregulates PANDER secretion in a dose-dependent manner [52, 
69, 70, 71]. Surprisingly, insulin was also found to upregulate PANDER secretion from 
pancreatic α-cells as well [69]. With the increase in glucagon and subsequent decrease in 
circulating insulin, PANDER is allowed to dominate glycemic regulation over glucagon via either 
a FOXO1 or CREB dependent pathway [51, 52, 54]. PANDER levels have been evidenced to be 
increased in fasting db/db mice, and this increase in PANDER negatively impacts the liver 
through FOXO1 and/or CREB to decrease basal insulin signaling and enhance HGP [51]. This 
increase in HGP seen in the PANTG via HEC clamp studies and evidenced through increased 
expression in gluconeogenic enzyme expression in ad-PANDER overexpressors, contributes to 
an overall increase in fasting hyperglycemia and plasma insulin content [54, 82] (Figure 22). 
 The PANKO-C57 corroborates the siRNA PANDER knockdown model where decreased 
fasting blood glucose levels were observed, though glucagon levels were similar in the PANKO-
C57 [51]. Although differences in FOXO1 and CREB (and p-CREB) levels were not able to be 
observed in the PANKO-C57 due to technical limitations, hepatic insulin signaling was 
upregulated, and levels of PEPCK were shown to be trending lower in PANKO-C57, indicating 
that when fasting; PANDER does, in fact, dominate basal levels of insulin to increase HGP. 
Because fasting plasma insulin levels were lower in the PANKO-C57 compared to WT, PANDER 
could potentially be working through an alternate mechanism to enhance HGP and increase 
fasting glycemia. Being that there was no significant difference in fasting plasma leptin levels in 
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the PANTG overexpressor and the PANKO-C57 exhibited significantly increased plasma leptin 
levels, this offers a suitable route for PANDER. Increases in leptin and leptin signaling in the 
brain are associated not only with increased fat mass, but with enhances in hepatic signaling 
through PI3K, suppression of HGP, and increased hepatic insulin sensitivity [96, 99, 100]. This 
presents an attractive mechanism for PANDER to act through, where PANDER could potentially 
act on/be secreted from the brain and decrease leptin signaling, ultimately leading to an 
increase in HGP and decrease in hepatic insulin sensitivity. Further, the siRNA PANDER 
knockdown db/db model with a known defect in leptin receptor signal transduction failed to 
report an enhancement of expression in all insulin proteins, perhaps due to the fact that they 
are lacking the synergism that exists between leptin and hepatic insulin sensitivity [51, 53]. As a 
whole, evidence from the PANKO-C57 phenotype indicates that the complete knockout of 
PANDER allows for enhanced basal insulin sensitivity when fasting, contributing to an overall 
decrease in fasting glycemia. 
 
Figure 22: PANDER’s Predicted Role in Glycemic Regulation in the Fasted State Based on 
PANKO-C57. (1) When fasting, blood glucose levels decrease, which (2) stimulate α-cells in pancreatic 
islets to secrete glucagon. Meanwhile, PANDER works either through a CREB or FOXO1 dependent 
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pathway to (3) decrease hepatic basal insulin signaling and increase HGP leading to (4) an increase in 
plasma insulin and increased glycemia.  
  
 PANDER in Type 2 Diabetes 
 Type 2 diabetes is a disease primarily characterized by 3 hallmarks- hyperglycemia, 
hyperinsulinemia, and hyperlipidemia, all of which are caused by secretagogues that have been 
shown to stimulate PANDER transcription and secretion [65, 66, 68, 69, 90]. When any/all of 
these disease states and secretagogues are present, the pancreatic islets are stimulated to 
further secrete PANDER and maintain basal levels of insulin. Because of the hyper conditions 
and given that PANDER levels are increased in mice modeling type 2 diabetes, PANDER could 
potentially stimulate its own secretion from both the pancreatic islets and hepatocytes, where 
PANDER is also present [51, 62]. This allows PANDER to impart its counterregulatory actions on 
insulin and bind to its putative target receptor on the liver to decrease insulin signaling, increase 
HGP, and decrease glycogen stores. The culmination of these events further perpetuates 
hyperinsulinemia, hyperglycemia, and hyperlipidemia as insulin and glucose are not being 
utilized, but instead remain in circulation. Thus, it appears that PANDER promotes a vicious 
cycle with regard to type 2 diabetes and facilitates the progression and potentially onset of the 
disease hallmarks (Figure 23). 
 PANKO-C57 mice, to begin, present with not only decreased fasting glucose levels, but 
also decreased fasting plasma insulin levels. This further supports the notion that PANDER is a 
main causative agent of fasting hyperglycemia and the subsequent hyperinsulinemia (due in 
part to counteraction of insulin resistance or potentially facilitation of insulin secretion), as was 
observed in young PANTG mice [96]. In terms of hyperlipidemia, PANKO-C57 mice, though they 
appear to be hyperlipidemic, they retain their hepatic insulin sensitivity, and the improved 
hepatic insulin signaling through SREBP-1 accounts for this observed hyperlipidemia both 
hepatically and in the plasma. In the fed, insulin-sensitive state, PANDER’s effects on glucose 
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homeostasis are minimal, as insulin imparts inhibitory effects on PANDER action perhaps simply 
by a concentration dependence. But when insulin resistance sets in, it appears as though insulin 
is potentially no longer capable of sufficiently counterracting PANDER. Instead, it appears that 
PANDER operates in a positive-feedback loop to enhance its own production from the 
pancreatic islets. PANDER binding to the liver membrane may also further stimulate PANDER 
expression and secretion from the liver in a similar positive feedback loop. PANKO-C57 mice are 
a model of insulin sensitivity and glucose tolerance compared to the PANTG and other PANDER 
overexpressors being that the PANKO-C57 mice, with no PANDER expression or secretion from 
any tissues, display reversal of a majority of metabolic abnormalities present in these 
overexpressors. With excess PANDER in circulation due to these disease hallmarks, all evidence 
points to PANDER as a causative factor in the progression of type 2 diabetes by continually 
increasing the severity of hyperinsulinemia, hyperlipidemia, and hyperglycemia and an attractive 
target for therapeutics in the treatment of type 2 diabetes. 
 
Figure 23: PANDER’s Predicted Role in Insulin Resistance and Type 2 Diabetes. In insulin 
resistant and type 2 diabetic individuals, where (1) hyperinsulinemia, hyperglycemia, and hyperlipidemia 
are present, (2) pancreatic islets secrete PANDER and insulin where PANDER is the dominant over insulin 
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and leads to an increase in PANDER secretion from pancreatic islets and the liver. (3) PANDER will 
decrease insulin sensitivity by decreasing hepatic insulin signaling, increasing HGP, and decreasing 
glycogen stores contributing to (4) a vicious cycle of hyperinsulinemia, hyperglycemia, and hyperlipidemia 
(adapted from Wilson, et al. 2011) [52]. 
  
 Perhaps the most telling data regarding PANDER and its negative regulatory effects on 
hepatic insulin sensitivity and fasting glycemia is its severe depleting effects on hepatic 
glycogen stores. Being that the PANKO-C57 had an over 100-fold greater amount of glycogen in 
the liver compared to WT and the PANTG revealed significantly decreased glycogen stores, this 
could potentially represent an additional mechanism of PANDER to induce fasting hyperglycemia 
[96]. We have concluded that the PANKO-C57 resembles that of an animal model of Glycogen 
Storage Disease (GSD). GSD, specifically Type 1 GSD, is a disorder caused by deficiency of 
G6Pase, an enzyme which performs the last step of gluconeogenesis and glycogenolysis to 
hydrolyze a phosphate group from glucose, leaving free glucose to be exported into the 
bloodstream [1, 2, 101, 102]. The disease, both in humans and in murine G6Pase-/- models, 
ends up manifesting itself through the following symptoms: hypoglycemia, significant liver 
enlargement, and hyperlipidemia both hepatically and in the serum, all of which were evident in 
the PANKO-C57 [101, 102]. The striking similarities between GSD Type 1 models and the 
PANKO-C57 could offer a potential mechanism for PANDER in increasing both fasting glycemia 
and gluconeogenic enzyme expression apart from increases in corticosterones and CREB 
signaling previously described [52, 54]. Additionally, GSD Type 1a is defined by a deficiency in 
the catalytic activity of G6Pase, which could be represented in the PANKO-C57 in that though 
the mice are not deficient in G6Pase expression (or PEPCK) in fasting or fed conditions shown 
via RT-PCR, perhaps G6Pase is building up due to a defect in its activity but not in its 
production [101, 102]. This then leads to a decrease in HGP, subsequent hypoglycemia, build-
up of glycogen in the liver with an increased liver mass, and increased triglycerides in the 
PANKO-C57. Lastly, with the recent findings involving PANDER and its role in various cancers 
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including oral squamous cell carcinoma and gastric cancer, this PANKO-C57 mouse model may 
offer future resources in the field of oncology [73, 77]. Given that PANDER expression was 
recently discovered to be downregulated in both of the aforementioned cancer types, our 
PANKO-C57 offers an optimal model to potentially study the progression of each cancer type in-
vivo [73, 77].  
 
Final Thoughts and Summary 
 In conclusion, this novel phenotypic characterization of the first PANDER knockout 
mouse on a C57BL/6J background offers valuable information regarding PANDER’s role in 
glucose homeostasis and insulin sensitivity. Not only do these PANKO-C57 mice display a 
significant increase in glucose tolerance and hepatic insulin sensitivity, but they exhibit an 
enhanced expression of key insulin signaling molecules throughout the entire insulin signaling 
cascade, indicating that PANDER disrupts insulin signaling as part of its detrimental actions on 
insulin sensitivity. Further, PANKO-C57 mice exhibit lower fasting glycemic measurements with 
decreased insulinemia and increased weights, perhaps to compensatory mechanisms involving 
leptin signaling and glycogen storage. Taken together, the characterization of this PANKO-C57 
model further indicates that PANDER plays a significant role in promoting the advancement and 
worsening of type 2 diabetes and its associated abnormalities during pathological states of 
dysregulation.   
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APPENDICES 
 
Appendix A: Primary Antibodies Utilized 
Table A1. Primary Antibodies and their Respective Catalog Numbers Used in SDS-PAGE in 
Chapter 3. 
Primary Anitbody Used Source 
IRS-1 (C-20) Santa Cruz Biotechnologies, Cat. # sc-559 
p-IRS-1 (Tyr 989) Santa Cruz Biotechnologies, Cat. # sc-17200 
p-PI3K p85α Santa Cruz Biotechnologies, Cat. # sc-12929 
Total Akt Cell Signaling Technology, Cat. # 4691 
p-Akt Thr 308 (244F9) Cell Signaling Technology, Cat. # 4056 
SREBP-1C (Mature & Precursor) (H-160) Santa Cruz Biotechnologies, Cat. # sc-8984 
Total ACC (C83B10) Cell Signaling Technology, Cat. # 3676 
p-ACC (Ser79) Cell Signaling Technology, Cat. # 3661 
Total AMPKα (23A3) Cell Signaling Technology, Cat. # 2603 
p-AMPKα (Thr172) Cell Signaling Technology, Cat. # 2535 
GAPDH (14C10) Cell Signaling Technology, Cat. # 2118 
Total Glycogen Synthase (15B1) Cell Signaling Technology, Cat. # 3886 
p-Glycogen Synthase (Ser641) Cell Signaling Technology, Cat. # 3891 
Total CREB Cell Signaling Technology, Cat. # 4820 
p-CREB (Ser133) Cell Signaling Technology, Cat. # 4276 
p-FOXO1 (Thr24)/FoxO3a (Thr32) Cell Signaling Technology, Cat. # 9464 
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Appendix B: 4005M Breeding Protocol for PANKO-C57 IACUC Approval 
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Appendix C: Experimental 4071 R Protocol IACUC Approval 
 
